分類: ACN Newswire

HONG KONG, Mar 29, 2026 - (ACN Newswire via SeaPRwire.com) - Against the backdrop of continued momentum in humanoid robots and embodied intelligence, Shoucheng Holdings (0697.HK) is rapidly gaining market attention for its expanding presence in the robotics sector. According to the latest 2025 Chairman’s Statement, the Beijing Robotics Industry Development Investment Fund, which the company co-manages, has achieved approximately fourfold growth in portfolio valuation over the past four years, demonstrating strong capabilities in deal sourcing and value realization. At the same time, Shoucheng Holdings has invested in more than 20 leading companies in embodied intelligence and robotics, covering multiple areas including humanoid robots, quadruped robots, medical robotics, and the low-altitude economy, gradually building a relatively comprehensive industry footprint.Based on disclosed projects, the company’s investment portfolio already includes a number of representative enterprises such as Unitree Robotics, Galbot, Xinghaitu, TowardPi Medical, Volant, and DEEP Robotics. Management has also previously disclosed that the funds under the company’s management have cumulatively invested more than RMB 2 billion in the robotics industry, completing over 40 transactions. As the valuations of leading projects continue to rise and exit timelines gradually progress, Shoucheng Holdings is expected to unlock profits in the future through fund distributions, management fees, and carried interest.Taking Unitree Robotics, which has submitted a listing application, as an example, based on minimum post-offering dilution calculations, the value of the relevant equity stake held by the Beijing Robotics Fund has increased from approximately RMB 520 million to approximately RMB 1.55 billion, generating about RMB 1 billion in book value appreciation. This also reflects, from another angle, the return potential accumulated by Shoucheng Holdings through its forward-looking positioning in the robotics sector.In addition to investment returns, another differentiated advantage of Shoucheng Holdings lies in its ability to combine industrial investment with asset operation capabilities. Leveraging managed scenarios such as parking facilities, industrial parks, and airports, the company can provide portfolio robotics companies with support in product display, testing, energy replenishment, operations and maintenance, and commercialization deployment, gradually forming a closed-loop model of “investment + scenarios + operations.” This not only helps improve the deployment efficiency of portfolio companies, but also has the potential to enhance the utilization efficiency and commercial conversion capability of the company’s assets.In terms of shareholder returns, the company proposed a total dividend of HKD 780 million for 2025, corresponding to a dividend yield of approximately 5.6%. While continuing to increase its investment in robotics and embodied intelligence, Shoucheng Holdings has also demonstrated an operating profile that balances growth potential with shareholder returns. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月29日 - (亞太商訊 via SeaPRwire.com) - 在人形機器人與具身智能持續升溫的背景下，首程控股（0697.HK）在機器人賽道的布局正加速進入市場視野。根據最新發布的2025年主席報告書，公司參與管理的北京機器人產業發展投資基金，投資組合估值在4年間實現約4倍增長，顯示出較強的項目挖掘和價值兌現能力。與此同時，首程控股已在具身智能與機器人領域投資20餘家頭部企業，覆蓋人形機器人、四足機器人、醫療機器人、低空經濟等多個方向，逐步形成較為完整的產業版圖。從已披露項目來看，公司投資版圖已涵蓋宇樹科技、銀河通用、星海圖、圖湃醫療、沃蘭特、雲深處等一批代表性企業。管理層此前亦透露，目前公司管理的基金已在機器人產業累計投資逾20億元，完成超過40筆交易。隨着頭部項目估值持續提升、退出節奏逐步推進，首程控股未來有望通過基金分配、管理費及業績報酬等方式實現利潤釋放。以已提交上市申請的宇樹科技為例，按公開發行後的最低攤薄口徑測算，北京機器人基金所持相關股權價值已由約5.2億元提升至約15.5億元，帶來約10億元賬面增值。這也從側面反映出首程控股在機器人賽道前瞻布局所積累的潛在回報空間。除投資收益外，首程控股的另一項差異化優勢，在於將產業投資與資產營運能力相結合。依託停車場、園區、機場等在管場景，公司可為被投機器人企業提供展示、測試、補能、運維及商業化落地支持，逐步形成「投資＋場景＋營運」的閉環模式。這不僅有助提升被投企業的落地效率，也有望增強公司資產的使用效率與商業轉化能力。在股東回報方面，公司2025年度擬派發總股息7.8億港元，對應股息率約為5.6%。在持續加碼機器人與具身智能布局的同時，首程控股亦展現出兼顧成長性與回報能力的經營特徵。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月28日 - (亞太商訊 via SeaPRwire.com) - 當一輛Robotaxi駛入停車樓，它所需要的早已不只是一個停車位，而是一整套支撐其運行的基礎設施體系，包括補能、調度、維保、數據連接，以及完整的無人化閉環能力。也正因此，傳統停車場的底層邏輯正在被重新定義：它不再只是停放車輛的靜態空間，而在加速演變為未來無人系統運行的重要節點。首程控股（0697.HK）管理層表示，未來停車場將成為規模最大的機器人運營基地，首程控股董事會主席趙天暘則在年報進一步揭示了這一判斷背後的邏輯：「我們看到的不只是當下的車位，而是未來數智化基礎設施的關鍵節點。」在這一認知下，停車場的角色正在發生變化，從傳統靜態交通配套空間，轉向承載機器人運行、調度與服務的基礎設施平台。理解這一轉型，關鍵在於把握傳統停車模式與「驛停車場（E Park）」模式之間的本質區別。在傳統模式下，停車場的收入主要來自停車收費，核心資產是車位資源，服務對象以車主為主，運營邏輯本質上是對空間和時長的管理，增長彈性相對有限。而在E Park模式下，停車場已不再是單一的空間租賃載體，而是升級為面向Robotaxi、Robovan及各類機器人的綜合服務平台。這種變化首先體現在收入結構上。傳統停車業務收入來源較為單一，而E Park模式則可以疊加調度服務費、充換電及託管費、運維及OTA服務費、廣告展示和智能業務對接費等多元收入，顯著拓寬盈利邊界。與此同時，停車場的核心資產也由單純的車位資源，升級為「場域資源＋補能設施＋調度能力＋機器人接入能力」的複合體系。換句話說，停車場未來的價值，不再主要取決於停了多少輛車，而在於能夠為多少無人系統提供多深度的服務。客戶結構也在同步變化。傳統停車場主要服務C端車主，而在E Park模式下，其服務對象進一步擴展為To B、To C、To Robot並存，既服務無人駕駛運營商，也服務終端用戶和機器人設備本身，形成新的基礎設施生態。與此同時，面向無人系統的停車場還可通過專用通道、集約化設計、補能設施和數據接口，實現24小時自動對接與全流程無人化閉環，從而提升空間利用效率和整體運營效率。而要把這一判斷轉化為可複製的現實路徑，關鍵就在於真實場景中的驗證與落地。首程控股選擇從高流量、高密度的交通樞紐和核心城市場景切入，推動機器人能力與停車資產深度結合。其中一個標誌性案例，是公司在北京首都機場T3停車樓引入松延動力Hobbs W1智能機器人，通過科技手段提升資產運營效率與旅客體驗；另一個案例，則是公司聯合被投企業萬勳科技，在成都環貿ICD地下停車場打造全國首個「自動充電機器人快閃體驗站」，推動停車場從單一停放空間邁向「停充一體」的智能運營場景，進一步驗證機器人技術與城市基礎設施的深度嵌入能力。從更宏觀的視角看，首程控股之所以能夠推動這一路徑落地，關鍵在於其擁有可承接新需求的資產底座。隨著Robotaxi、Robovan以及具身智能機器人加快進入城市場景，城市將需要大量分散式節點承擔補能、調度和維保功能。相比新建設施，停車場天然具備區位分布廣、空間條件成熟、電力接入便利、資產屬性清晰等優勢，因此成為最現實、最具效率的承接載體。在這一趨勢下，首程控股的網絡化布局優勢正加快轉化為現實能力。公司在全國管理逾百個停車場項目，總面積達數百萬平方米，覆蓋核心經濟區域，具備標準化改造與規模複製的基礎。這意味著，其原本分散的靜態停車資源，正有望被重構為覆蓋多城市、多節點的機器人運營基礎設施網絡。與此同時，運營層面的改善也為這一轉型提供了支撐。2025年，公司車位周轉率提升7.1%、車位滿停率達到55%、創新業務收入佔比達到20%，顯示出其通過AI技術應用、精細化運營和場景開放，正推動停車場由傳統存量資產向平台型、增長型資產轉變。由此，「未來停車場將成為規模最大的機器人運營基地」對首程控股而言，已不只是前瞻判斷，而是一條正在被持續驗證、並有望實現規模複製的現實路徑。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 28, 2026 - (ACN Newswire via SeaPRwire.com) - When a Robotaxi enters a parking structure, what it needs is no longer just a parking space, but a full infrastructure system to support its operations - including energy replenishment, dispatching, maintenance, data connectivity, and a complete fully autonomous end-to-end operational capability. For that reason, the underlying logic of the traditional parking lot is being redefined: it is no longer merely a static space for vehicle storage, but is rapidly evolving into a critical node for the operation of future unmanned systems.In its 2025 Annual Report, Shoucheng Holdings Limited (0697.HK) judged that parking lots will become the largest robot operating bases in the future. Zhao Tianyang, Chairman of the Board of Shoucheng Holdings, further explained the logic behind this view in the annual report: "What we see is not merely today's parking spaces, but the key nodes of future smart digital infrastructure." Based on this understanding, the role of the parking lot is changing - from a traditional supporting space for static transport to an infrastructure platform that supports robot operation, dispatch, and services.To understand this transformation, the key is to grasp the fundamental difference between the traditional parking model and the "E Park" model. Under the traditional model, parking lot revenue mainly comes from parking fees, the core asset is parking space resources, the main customers are vehicle owners, and the operating logic is essentially the management of space and time, with relatively limited growth potential. Under the E Park model, however, the parking lot is no longer a single space-leasing asset, but is upgraded into an integrated service platform for Robotaxis, Robovans, and various types of robots.This change is first reflected in the revenue structure. Revenue sources in the traditional parking business are relatively simple, whereas the E Park model can layer in multiple income streams, including dispatch service fees, charging or battery-swapping and custody fees, O&M and OTA service fees, advertising fees, and smart service integration fees, significantly broadening the boundaries of profitability. At the same time, the core assets of the parking lot are upgraded from mere parking space resources to a composite system of "site resources + energy-replenishment facilities + dispatching capabilities + robot access capabilities." In other words, the future value of a parking lot will no longer depend primarily on how many cars it accommodates, but on how deeply it can serve how many unmanned systems.The customer structure is also changing in parallel. Traditional parking lots primarily serve end-user vehicle owners. Under the E Park model, however, the service base expands to a coexistence of To B, To C, and To Robot - serving autonomous driving operators, end users, and robot devices themselves, thereby forming a new infrastructure ecosystem. At the same time, parking lots designed for unmanned systems can enable 24-hour automatic docking and a fully unmanned closed loop throughout the process through dedicated lanes, space-efficient design, energy-replenishment facilities, and data interfaces, thereby improving space utilization and overall operational efficiency.To turn this judgment into a replicable path in the real world, the key lies in validation and implementation in real scenarios. Shoucheng Holdings has chosen to begin with high-traffic, high-density transport hubs and core urban scenarios, promoting deep integration between robotic capabilities and parking assets. One landmark case is the introduction of the Hobbs W1 intelligent robot from Noetix Robotics at the Terminal 3 parking building of Beijing Capital International Airport, where technology was used to enhance both asset operating efficiency and passenger experience. Another example is Shoucheng Holdings' collaboration with its portfolio company Wisson Robotics to build the country's first automatic charging robot pop-up experience station in the underground parking lot at Chengdu IFS ICD, driving the parking lot's evolution from a single parking space into an intelligent operating scenario integrating parking and charging, and further validating the deep embedding of robotic technology into urban infrastructure.From a broader macro perspective, the reason Shoucheng Holdings has been able to advance this path lies in its ownership of an asset base capable of accommodating new demand. As Robotaxis, Robovans, and embodied intelligent robots accelerate into urban scenarios, cities will require a large number of distributed nodes to undertake energy replenishment, dispatching, and maintenance functions. Compared with building new facilities from scratch, parking lots naturally possess advantages such as wide geographic distribution, well-developed spatial conditions, easy access to power supply, and clearly defined asset characteristics. They have therefore become the most practical and efficient carriers for this new demand.Against this backdrop, Shoucheng Holdings' advantage in network-based deployment is being rapidly converted into real capability. The Company manages more than 100 parking lot projects nationwide, with a total area of several million square meters, covering core economic regions and providing a foundation for standardized retrofitting and large-scale replication. This means that its previously scattered static parking resources are now poised to be restructured into a multi-city, multi-node robot operating infrastructure network. At the same time, improvements at the operational level are also supporting this transition. In 2025, the Company's parking space turnover rate increased by 7.1%, its full-occupancy rate reached 55%, and innovative business revenue accounted for 20% of total revenue, demonstrating that through the application of AI technologies, refined operations, and expanding scenario applications, it is driving parking lots' transformation from traditional legacy assets into platform-based, growth-oriented assets.Accordingly, for Shoucheng Holdings, the proposition that "parking lots will become the largest robot operating bases in the future" is no longer merely a forward-looking judgment. It is a practical path that is being continually validated and is expected to achieve replication at scale. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月28日 - (亞太商訊 via SeaPRwire.com) - 3月27日，中創新航科技集團股份有限公司（「中創新航」或「公司」，股票代碼：3931.HK）公佈截至2025年12月31日止年度（「報告期」）經審核綜合全年業績。公告顯示，公司全年總收入人民幣44,400.07百萬元，同比增長約60%；年內利潤人民幣2,095.22百萬元，同比增長超過140%，盈利能力實現跨越式提升，高質量發展態勢持續凸顯。在核心業務領域，公司動力電池與儲能電芯市場份額均實現大幅攀升，其中2025年10月動力電池裝車量更是躋身全球前三，2026年開年商用電池出貨量同比暴增630%，成為行業增長亮點。全球市場縱深拓展，高端化與規模化雙突破2025年全球新能源產業高速增長，動力電池、儲能電芯出貨量均大幅攀升，海外市場成為核心增長極。中創新航憑藉全場景產品力，實現高端化與規模化發展雙提速。公司乘用車市場市佔率再創新高，5C超充電池獨家配套小鵬新P7超長續航等爆款車型，助力小鵬新P7創造了24小時行駛3961km的新紀錄，實現月銷超2萬台套，市場競爭力行業領跑。同時，公司在新客戶拓展上，一方面成功切入豐田、大眾、現代等國際車企供應鏈，全球化佈局持續提速；另一方面，與華為鴻蒙智行、小米等頭部品牌持續深化合作，為2026年實現批量配套做好了全方位的準備。商用車領域亦增長強勁，2025年出貨量實現倍數級增長，新公告車型超468款，實現全場景覆蓋，2026年開年出貨同比暴增630%；歐洲軌交、大巴項目順利落地，連續斬獲海外客戶獎項。在儲能市場，中創新航海內外雙線突破，海外進入南非、拉美、美國、以色列等區域頭部供應商名錄，新一代「至久」600Ah+電芯獲批量定點；國內與國家電投、三峽新能源等頭部企業深化合作，全品類儲能市場佈局完成。此外，公司前瞻性佈局船舶、低空、機器人等新能源未來賽道，這一精準卡位成為資本市場關注的核心亮點。船舶領域已落地多個標杆項目並實現規模化交付，形成業績穩定增長支撐；低空領域憑藉固態電池核心技術賦能，飛行汽車配套電池順利量產下線且拿下eVTOL主力機型獨家定點，深度契合低空經濟萬億賽道的發展紅利；機器人領域則依託全固態電池技術突破完成產品佈局，相關產品即將開啟批量交付，提前搶佔人形機器人能源核心賽道，為公司後續業績增長打開全新增量空間。技術持續引領，全場景產品矩陣全面進階2025年，中創新航以全場景需求為牽引，在高性能電池、全固態電池、先進製造等領域實現多項關鍵突破，「頂流」、「至遠」、「至久」、「無界」等系列產品持續引領行業技術方向。其中，超充與高功率電池技術領跑，5C超充電池大規模商用，10C超充電池2025年完成設計開發；針對HEV/PHEV車型開發的20C高功率電池，已配套吉利、東風量產交付；針對超跑/賽車豪華細分市場開發的25C高功率電池，具備兆瓦級放電能力，已完成產品樣件的測試開發；頂流高能圓柱電芯實現量產，並已量產配套行業頭部Evtol客戶,實現市佔率第一。儲能與商用電池技術同步升級，「至遠」系列實現重卡2C超充、10年200萬公里長壽命，輕商產品續航超350公里；「至久」系列588Ah、684Ah大電芯，實現3年零衰減、15000+次循環，重新定義行業標準。在新型電池技術領域，固液混合與全固態電池技術獲重大突破。其中，400Wh/kg固液混合電池已率先搭載新能源商用車，實現批量裝機；450Wh/kg「無界」全固態電池完成原創體系完成試製驗證，性能行業領先。與此同時，低空、機器人等新興賽道的商業化進程正加速推進，有望助力公司進一步擴大全球市場份額。此外，公司還將通過「技術創新＋管理創新」雙輪驅動，在追求極致性能與極致成本中鍛造面向未來的系統性競爭力。AI+能源戰略深化，全鏈路賦能產業升級在技術突破的基礎上，中創新航以科技創新為引擎，以「AI+能源」戰略為指引，堅持科技創新與產業創新的深度融合，面向未來進行研發布局，建立新技術與產品開發－多市場應用－規模化交付－精細化運營－技術迭代升級的正向循環機制，深度契合當前AI與新能源融合的產業發展趨勢。目前，公司已形成覆蓋華東、華南、華西、華北、華中及歐洲、東盟的全球產業集群，為公司業務全球拓展及長期高質量發展提供堅實保障。隨著全球能源轉型進程加速，行業整體需求將持續快速增長，新興的場景將不斷湧現，預計公司的市場份額和盈利能力將進入加速增長的階段，全球競爭力和行業影響力將進一步提升。關於中創新航集團有限公司中創新航（3931.HK）是專業從事鋰電池、電池管理系統及相關整合式產品和鋰電池材料的研製、生產、銷售和市場應用開發的新能源高科技企業。作為電池專家，公司致力於構建全方位能源運營體系，為以動力及儲能為代表的新能源全場景應用市場提供完善的產品解決方案和全生命週期管理。目前，公司已建立江蘇、福建、四川、湖北、安徽、廣東等多個產業基地，完成全方位國內產業佈局，同時已設立歐洲產業基地、泰國產業基地，大力拓展海外產業佈局，打造擁有規模化智慧製造實力的國際化領先企業。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 28, 2026 - (ACN Newswire via SeaPRwire.com) - On March 27, CALB Group Co., Ltd. ("CALB" or "the Company," stock code: 3931.HK) announced its audited annual results for the year ended 31 December 2025 (the "Reporting Period"). During the Reporting Period, the Company’s total revenue for the year was RMB 44,400.07 million, representing a year-on-year increase of 60%; profit for the year was RMB 2,095.22 million, a year-on-year surge of over 140%, demonstrating a leap in profitability and continued momentum for high-quality development.In core business sectors, the Company’s market share for both power batteries and energy storage cells climbed significantly. In October 2025, CALB’s power battery installations reached a historic milestone, ranking among the global top three for the first time on a monthly basis. In early 2026, the Company stood out in the battery industry again with a huge growth of 630% YoY in the commercial EV sector.Deepening Global Market Presence with Dual Breakthroughs in Premium Market Positioning and Large-Scale ProductionIn 2025, as the global new energy industry flourished, shipments of power batteries and energy storage cells soared, with overseas markets becoming the core growth engine. Backed by all-scenario product capabilities, CALB accelerated its strategic layout toward both premium positioning and large-scale development.The Company’s market share in the passenger vehicle sector reached a new high. Its 5C super-charged battery, which has reached a monthly delivery sale of 20,000+ sets, exclusively supports popular models such as XPeng’s new P7 long-range version, supporting Xpeng further enhance its market competitiveness with a record-breaking driving mileage of 3,961km within 24h. Furthermore, CALB successfully entered the supply chains of international OEMs such as Toyota, Volkswagen, and Hyundai. Simultaneously, the Company deepened strategic partnerships with HUAWEI and Xiaomi, laying the groundwork for mass-scale delivery in 2026.The commercial vehicle segment also saw explosive growth, with shipments achieving a multiple-fold increase in 2025. With over 468 new vehicle models announced, the Company achieved full-scenario coverage and showed strong momentum as commercial battery shipments surged 630% YoY in early 2026. Overseas, the Company secured major rail transit and bus projects in Europe and won multiple international client awards.In the energy storage market, CALB achieved dual breakthroughs. Internationally, the Company entered the top-tier supplier lists in South Africa, Latin America, the U.S., and Israel. The next-generation “ZHIJIU” 600Ah+ cell secured mass production nominations. Domestically, partnerships with giants like SPIC (State Power Investment Corporation Limited) and CTG (China Three Gorges Corporation) were strengthened, further advancing the all-category energy layout in energy storage.Furthermore, the Company has established a forward-looking presence in emerging new energy sectors such as ship, low-altitude economy, and robotics, which represents a core highlight for the capital markets. In the shipping sector, several benchmark projects have already been implemented with large-scale deliveries, providing solid support for stable earnings growth. In the low-altitude sector, powered by core solid-state battery technologies, the Company has successfully commenced mass production of batteries for flying cars and secured exclusive nominations for major eVTOL models, perfectly aligning with the development trend of a trillion-dollar market. In the robotics sector, the Company has completed its product layout based on breakthroughs in all-solid-state battery technology. With batch deliveries set to begin, the Company is preemptively securing its position in the core energy track for humanoid robots, opening up significant growth opportunities for its future performance.Continuous Technology Leadership and All-Scenario Product Matrix AdvancementIn 2025, CALB achieved key breakthroughs in high-performance batteries, solid-state batteries, and advanced manufacturing. Product series such as “UP,” “ZHIYUAN,” “ZHIJIU,” and “Boundless” continue to define industry trends.Specifically, CALB is leading the way in super-charged and high-power battery technologies. The Company’s 5C super-charged batteries have reached large-scale commercialization, while the 10C super-charged batteries completed design and development in 2025. The 20C high-power batteries developed for HEV/PHEV models have been delivered for mass production to Geely and Dongfeng. For the luxury supercar and racing segments, the Company has completed prototype testing of its 25C high-power batteries, which boast megawatt-level discharge capabilities. Additionally, the advanced R46 cells have reached mass production and are being supplied to top-tier eVTOL customers, securing the No.1 market share in the sector.Technological upgrades were also synchronized across energy storage and commercial battery sectors. The “ZHIYUAN” series achieved 2C super-charged for heavy-duty trucks and a long lifespan of 10 years or 2 million kilometers, while light commercial EV batteries can support an upgraded mileage of over 350 kilometers. The “ZHIJIU” 588Ah/684Ah cells achieve zero degradation for 3 years and 15,000+ cycles, with an energy density of 450Wh/L.Significant breakthroughs were made in next-generation battery technologies, specifically in hybrid solid-liquid and solid-state batteries. The 400Wh/kg hybrid solid-liquid battery took the lead in powering new energy commercial vehicles with batch installations. The 450Wh/kg “Boundless” solid-state battery completed its original system prototype verification with industry-leading performance. Meanwhile, the commercialization process in emerging sectors such as low-altitude economy and robotics is accelerating, which is expected to help the Company further expand its global market share. In addition, the Company will continue to be driven by the dual engines of “technological innovation and management innovation,” forging systematic competitiveness for the future by pursuing excellence in both performance and cost management.“AI + Energy” Strategy: Empowering Industrial UpgradingBuilding on technological breakthroughs and guided by the “AI + Energy” strategy, CALB is driven by technological innovation and guided by the “AI + Energy” strategy, adhering to the deep integration of technological innovation and industrial innovation. Propelled by a future-oriented R&D layout, the Company has established a positive feedback loop of “new technology and product development – multi-market application – scaled delivery – refined operations – technological iteration and upgrade”—fully aligning with the current industrial trend of convergence between AI and new energy.Currently, CALB has established global industrial clusters across China, Europe, and ASEAN, providing a solid foundation for its global business expansion and long-term high-quality development.As the global energy transition accelerates, global demands are poised for sustained and rapid growth, with emerging application scenarios continuously surfacing. It is anticipated that the Company’s market share and profitability will enter a phase of accelerated expansion, further bolstering its global competitiveness and industry influence.About CALBCALB is a new energy enterprise specializing in the research, production, sales, and market application development of lithium batteries, battery management systems, and related integrated products and lithium battery materials. As Battery Expert, we aim to build a comprehensive energy operation system, to provide complete product solutions and full life-cycle management for the new energy application market, represented by power and energy storage.Currently, CALB has completed an all-round layout in domestic by setting up industrial bases in Changzhou, Xiamen, Wuhan, Chengdu, Hefei, Jiangmen and Meishan. Meanwhile, CALB has set up bases in Europe and ASEAN, vigorously expanding the layout all over the world to become a global leading enterprise with large-scale intelligent manufacturing capabilities. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

 Financial HighlightsFor the year ended 31 December (RMB’000)20252024Change%Revenue1,004,586969,854+3.6%Gross profit544,651539,894+0.9%Profit before tax318,601298,331+6.8%Profit for the year242,548223,618+8.5% HONG KONG, Mar 28, 2026 - (ACN Newswire via SeaPRwire.com) - 27 March 2026, Shanghai Gench Education Group Limited (“Gench Education” or the “Company”, together with its subsidiaries, the “Group”, Stock Code:1525.HK) -- the leading higher vocational education group in East China and the largest higher vocational education group in Shanghai, delightedly announced its consolidated financial results for the year ended 31 December 2025 (the “Reporting Period”).During the Reporting Period, the Group recorded revenue of approximately RMB1,005 million, representing an increase of 3.6% year-on-year (“YoY”). Gross profit was RMB545 million, up 0.9% YoY; Profit for the year of approximately RMB243 million, a YoY rise of 8.5%. Basic earnings per share attributable to ordinary equity holders of the parent were RMB 0.61, up 7.0% year-on-year. The growth was mainly driven by the increase in student enrolment, optimization of tuition rates and expansion of education-related services. The Group proposes to declare a final dividend of HKD$0.04 per share for 2025. Together with the interim dividend of HK$0.10 per share for the six months ended 30 June 2025, the total dividend for 2025 will be HK$0.14 per share, maintaining a stable dividend policy to reward shareholders.Policy Dividends Deliver with Precision, Lingang Advantages Unleash Development PotentialIn 2025, the national “Outline of the Plan for the Construction of a Stronger Education State (2024-2035)” and the industry-education integration policies of Lingang New Area jointly created a favorable policy environment for the Group’s development. As the only private university in Lingang New Area, Shanghai Jian Qiao University (the “University”) has closely aligned with the regional industrial layout and seized the opportunities brought by the clustering of strategic emerging industries including integrated circuits, life health and high-end equipment manufacturing, achieving precise matching between educational resources and industrial demands. “The Shanghai ‘Lingang Science Innovation Town’ Construction Plan” clearly proposes to leverage the science and technology innovation resources of universities. Taking this opportunity, the University has become a core participant in industry-education integration in Lingang. It has not only obtained special policy and resource support, but also transformed geographical advantages into unique competitiveness through targeted talent training and joint technological research and development. As of 31 August 2025, 77.5% of the University’s 2025 graduates were employed in the Yangtze River Delta region and 59.2% in Shanghai, deeply integrating into the regional development ecosystem.Digital-Intelligent Transformation Yields Remarkable Achievements, Teaching Quality Scales New HeightsDriven by technological innovation in education and teaching upgrading, the University achieved a number of landmark results in curriculum digitalization and smart campus construction in 2025. In terms of curriculum innovation, the University has built a multi-dimensional curriculum system covering “AI + courses”, “industry-education integration courses” and other types. A total of its 26 courses were approved as Shanghai higher education municipal level key courses, among which “AI + courses” accounted for 50%. “Fundamentals of Gemstone Geology and Crystallography” offered by College of Jewelry was successfully selected as a national “Online/Offline Hybrid First-Class Course”, achieving a breakthrough in the construction of national first-class courses. The University has developed a total of 1,253 online open courses, continuously expanding the scale of digital teaching resources. In smart campus construction, the University continues to deepen the upgrading and modification of teaching and scientific research instruments and equipment as well as teaching laboratories, independently developed smart platforms such as the Cloud Teaching Centre and Cloud Examination Centre, and embedded AI, 5G, VR (virtual reality) and other technologies into the teaching reform process. In addition, the University has built the DeepSeek Gench Education Applied Big Model and launched three smart systems for teaching, management and services, achieving refined campus management and personalized services.In terms of faculty development, as of 30 September 2025, among the full-time teachers, the master degree or higher accounted for 86.4%, the doctoral degree accounted for 28.8%, the senior title accounted for 38.6%, and the double-position accounted for 47.8%. The University has promoted the development of teaching staff towards high quality and professionalism through faculty mentoring, specialized training, and encouraging teachers to take part in various teaching competitions. In 2025, the teaching team won numerous awards in national and regional teaching competitions, earning industry-wide recognition for their capabilities. Meanwhile, the University’s disciplinary strength maintained a leading position. According to “2025 First-class Majors Ranking (Application-oriented) in China” by CUAA.net, its 29 majors ranked among top 10 in China, among which 13 majors ranked first nationwide. The employment rate of year 2025 graduates reached 99.4%, the college-entrance rate reached 5.8%, and the rate of studying abroad reached 5.3%, particular with 94 graduates admitted to top 50 universities/colleges and 123 graduates admitted to top 100 universities/colleges in QS World University Rankings. These results demonstrate that the quality of talent training has been widely recognized.Industry-Education Integration Accelerates, Building a Collaborative Ecosystem for School-Enterprise SynergyIn 2025, the University accelerated the construction of an industry-education integrated university and established a “three-in-one” operation model of “Secondary Colleges + Industrial Colleges + Entity Companies”, forming a multi-dimensional collaborative education ecosystem. The University has made comprehensive progress in its industry college development. The University has established the Medical Engineering Industry College and the Live Streaming Economy Industry College, and meanwhile actively drove the construction of the Big Data Industry College, the IC Industry College and the Intelligent Manufacturing Industry College. The “Digital Smart Manufacturing” and “Integrated Circuit” industrial colleges had been awarded as Shanghai municipal key modern industrial colleges. Major platforms were successively launched in a string. The national level platform “IC Packaging and Testing Industry-Talent Collaboration and Innovation Centre” & Lingang Industry-Education Integrated Practice Base was created. Lingang Jewelry Art Centre was opened, integrating public exhibition, entrepreneurship incubation, science generalization & education, appraisal & design, fashion & consumption among other functions. During the year, the University conducted 8 key industry-education integrated projects, and added 20 new industry-education integrated courses with teaching materials, further deepening school-enterprise collaboration. School facilities were continuously improved. The phase four campus facilities were fully operational in March 2025, with a total gross floor area of approximately 86,400 square meters, including a teaching and training building, talent apartments and a multi-functional research and development center, providing a solid foundation for school-enterprise joint research and student practical training.International Cooperation Reaches a New Level, Lifelong Education System Steadily ImprovesThe Group has been deeply engaged in private higher education for 25 years, with its brand reputation and industry position steadily rising. According to CUAA.net, the University has ranked third among Category I private universities in China for five consecutive years and first among private universities in the Yangtze River Delta for seven consecutive years. It has passed the reexamination of “National Model Unit of Civilization” three times and won many honors including the first batch of “Lei Feng Spirit University Demonstration Education Bases” and “Contribution Award for Promoting Lei Feng Spirit in the New Era”. Its quality of education has received wide recognition from society. International business continued to expand. In 2025, the University contracted with 11 overseas famous universities/colleges in Germany, United Kingdom, New Zealand, Thailand and other countries, received cumulatively 43 batches of delegations of overseas famous institutions, and published more than 30 foreign/overseas exchange projects (like UN international NGO training, overseas famous university/college visit, overseas famous enterprise internship), continuously broadening channels for teachers and students to exchange overseas.The lifelong education system has been continuously improved to meet the diverse learning demands of all communities. As of 31 December 2025, the number of adult students of the continuing education programs reached 3,760, and more than 400 types of vocational skill certificate training were provided. In addition, as a continuing education base for high end equipment industry workers and a continuing education base for fashion consumption and logistics industry workers, the University applies for Shanghai “dual system” workers continuing education higher education pilot base (incubation) project, and the project is initiated.Looking to the future, Mr. Zhao Donghui, Chairman of the Board and Executive Director of Gench Education, stated: “The steady growth of the Group’s performance in 2025 confirms the effectiveness of the high-quality development strategy. Going forward, we will continue to take digital and intelligent transformation as the driver, deepen the industry-education integration collaborative education model, seize the historic opportunity of building Lingang New Area into a world-class science innovation town, further optimise the professional layout, enhance the teaching capacity and improve the campus ecosystem. We are committed to preliminarily completing the transformation of an industry-education integrated university by 2030 and fully accomplishing it by 2035, building a world-class private university with international influence, and sharing the dividends of high-quality development of vocational education with all shareholders.”About Shanghai Gench Education Group LimitedGench Education (Stock Code: 1525.HK) is a higher vocational education group which provides undergraduate education and junior college education, focusing on high-quality schooling for the provision of excellent education for students. The Group operates Shanghai Jian Qiao University, being the domestic leading private university, at Lingang New Area of China (Shanghai) Pilot Free Trade Zone. As measured by the number of full-time students enrolled in the 2025/26 school year, the University is the largest private university in Shanghai and is also a leading private university in the entire Yangtze River Delta. According to CUAA.net, the University ranked third among all category I private universities in China for five consecutive years and first among private universities in the Yangtze River Delta for seven consecutive years. Over 25 years of operation, the schooling quality of the University ranked in the forefront of peer universities, which has accumulated a solid brand reputation. Since 2004, the University has been consecutively awarded “Shanghai Civilized Unit” over 18 years. The University has won numerous honorary titles such as “National Model Unit of Civilization”, “Shanghai Garden Unit”, “Shanghai Safe and Civilized Campus”, etc. The University has also been granted reputable title of “Lei Feng Spirit College Demonstration Education Base” among the first batch of universities in the PRC in April 2024, and was awarded the “Contribution Award for Promoting Lei Feng Spirit in the New Era” in September 2024.This press release is issued by Porda Havas International Finance Communications Group on behalf of Shanghai Gench Education Group Limited. For further information, please contact:Porda Havas International Finance Communications GroupE-mail: gench.hk@pordahavas.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

 財務摘要截至12月31日止年度(人民幣千元)20252024變化%收入1,004,586969,854+3.6%毛利544,651539,894+0.9%除稅前溢利318,601298,331+6.8%年內溢利242,548223,618+8.5%香港, 2026年3月28日 - (亞太商訊 via SeaPRwire.com) - 2026年3月27日，華東地區領先、上海最大型的高等職業教育集團 - 上海建橋教育集團有限公司(「建橋教育」或「公司」，連同其附屬公司，統稱「集團」，股份代號：1525.HK)，欣然公佈截至2025年12月31日止年度(「報告期內」)之全年業績。報告期內，集團錄得收入約10.05億元(人民幣，下同)，同比增長3.6%；毛利約5.45億元，同比增長0.9%；年內溢利約2.43億元，同比增長8.5%。母公司普通權益持有人應占每股盈利0.61元，同比增長7.0%。業績增長主要得益於學生人數增加、學費標準優化及教育相關服務擴張。集團擬派發2025年末期股息每股0.04港元，連同截至2025年6月30日止六個月的中期股息每股0.1港元，2025年總股息為每股0.14港元，股息政策保持穩定，回饋股東支持。政策紅利精准落地，臨港優勢釋放發展潛能2025 年，國家《教育強國建設規劃綱要 (2024-2035 年)》與臨港新片區產教融合專項政策形成合力，為集團發展創造優越政策環境。作為臨港新片區唯一民辦高校，上海建橋學院（「學院」）深度對接區域產業佈局，緊抓集成電路、生命健康、高端裝備製造等戰略新興產業集聚機遇，實現教育資源與產業需求的精准匹配。《上海市「臨港科創城」建設方案》明確提出發揮高校科創資源優勢，學院以此為契機成為臨港產教融合核心參與者，不僅獲得專項政策與資源支持，更通過人才定向培養、技術聯合研發等方式，將區位優勢轉化為獨特競爭力。截至2025年8月31日，學院2025屆畢業生長三角地區就業占比77.5%，上海地區就業占比59.2%，深度融入區域發展生態。數智化轉型成效顯著，教學品質再攀新峰學院以技術創新驅動教育教學升級，2025 年在課程數字化、校園智慧化等領域取得多項標誌性成果。課程創新方面，構建覆蓋「AI + 課程」「產教融合課程」等多類型的立體化課程體系，26 門課程獲批上海高校市級重點課程立項，其中「AI + 課程」占比高達 50%。珠寶學院《寶石地質基礎及結晶礦物學》成功入選國家級「線上線下混合式一流課程」，實現國家級一流課程建設中零的突破；累計建設 1,253 門線上開放課程，數字化教學資源規模持續擴充。智慧校園建設上，學院持續深化對教學科研儀器設備及教學實驗室的升級改造，自主研發雲教學中心、雲考試中心等智慧平臺，並把 AI、5G、VR（虛擬現實）等技術嵌入教學改革過程。此外，學院還搭建 DeepSeek 建橋教育應用大模型，推出教學、管理、服務三大智慧體，實現校園管理精細化與服務個性化。師資隊伍建設方面，截至 2025 年 9 月 30 日，專任教師中，碩士及以上學位占比達86.4%，博士學位占比達28.8%，高級職稱占比達38.6%，雙師型占比達47.8%，通過導師帶教、專題培訓、鼓勵教師參加各類教學競賽等方式，推動教師隊伍向高素質、高技能方向發展。2025 年，教師團隊在全國及區域教學競賽中屢獲大獎，教學能力獲行業認可。與此同時，學院學科專業實力持續領先，根據中國校友會網《2025 中國大學一流專業排名 (應用型)》，學院29 個專業位列全國前 10 名，13 個專業排名全國第一。2025 屆畢業生就業率高達 99.4%，升學率 5.8%，出國率 5.3%，其中 94 人進入 QS 前 50 名高校留學，123 人進入 QS 前 100 名高校留學，人才培養品質獲社會廣泛認可。產教融合轉型提速，打造校企協同育人生態2025 年，學院加速推進產教融合型大學建設，構建「二級學院 + 產業學院 + 實體公司」三位一體運行模式，形成多維度協同育人生態。產業學院建設全面鋪開，新增醫工產業學院、直播經濟產業學院，同時積極推進大數據產業學院、集成電路產業學院、智能製造產業學院的建設，此前，學院「數聯智造」「集成電路」兩大產業學院已獲評上海市級重點現代產業學院。重大平臺相繼落地，國家級「集成電路封測產才協同創新中心」暨臨港產教融合實踐基地正式落戶，臨港珠寶藝術中心投入運營，集公益展覽、創業孵化、科普教育、鑒定設計、時尚消費等多功能於一體；全年開展 8 個重點產教融合專案，新增 20 門產教融合課程與教材，校企合作深度持續加強。校園硬體不斷完善，第四期校舍於 2025 年 3 月全面投用，總建築面積約 86,400 平方米，包含教學培訓大樓、人才公寓及多功能研發中心，為校企聯合研發、學生實踐訓練提供堅實基礎。國際合作邁上新臺階 ，終身教育體系持續完善集團深耕民辦高等教育 25 年，品牌口碑與行業地位穩固提升。根據中國校友會網，學院連續五年蟬聯中國民辦大學排名 I 類第三名，連續七年位居長三角民辦大學榜首；三度通過「全國文明單位」审查，榮獲「全國首批雷鋒精神高校示範教育基地」和「新時代傳播雷鋒精神貢獻獎」等多項榮譽，辦學品質獲社會廣泛認可。國際化業務持續拓展，2025 年新簽約德國、英國、新西蘭、泰國等 11 所海外名校，接待海外知名院校代表團訪問 43 批次，全年發佈 30 餘個國 (境) 外交流專案，涵蓋聯合國國際組織實訓、海外名校訪學、海外名企實習等多種類型，師生海外交流渠道持續暢通。終身教育體系不斷完善，可以滿足社會各界多樣化學習需求。截至2025年12月31日，成人繼續教育在職學生達 3,760 人，累計提供 400 餘種職業技能證書培訓。此外，學院圍繞高端裝備行業職工繼續教育基地和時尚消費與物流行業職工繼續教育基地，申報上海市「雙元制」職工繼續教育高校試點基地（培育）專案，並成功獲得立項。展望未來，建橋教育董事會主席及執行董事趙東輝先生表示：「2025 年集團業績的穩健增長，印證了高質量發展戰略的有效性。未來，我們將繼續以數智化轉型為驅動，深化產教融合協同育人模式，緊抓臨港新片區建設國際一流科創城的歷史機遇，進一步優化專業佈局、強化師資隊伍、完善校園生態。我們致力於在 2030 年初步完成、2035 年全面建成產教融合型大學，打造具有國際影響力的中國一流民辦大學，與全體股東共同分享職業教育高質量發展的紅利。」關於上海建橋教育集團有限公司建橋教育（股份代號：1525）為一家提供本科及專科教育的高等職業教育集團，專注高質量辦學，為學生提供優質教育。集團於中國（上海）自由貿易試驗區臨港新片區運營國內領先民辦大學上海建橋學院，按2025/26學年的全日制在校生人數而言，本學院為上海最大型的民辦大學，亦為整個長江三角洲領先的民辦大學。根據中國校友會網，學院連續五年蟬聯中國民辦大學排名I類第三名，並連續七年蟬聯長三角民辦大學第一名。辦學25年來，學院辦學品質處於同類院校頂尖水準，品牌積澱廣受讚譽。自2004年起，學院連續18年獲九屆「上海市文明單位」榮譽稱號，多次獲評「全國文明單位」「上海市花園單位」「上海市安全文明校園」等榮譽稱號，於2024年4月獲選全國首批「雷鋒精神高校示範教育基地」，於2024年9月榮獲「新時代傳播雷鋒精神貢獻獎」。此新聞稿由博達浩華國際財經傳訊集團代上海建橋教育集團有限公司發佈。如有垂詢，請聯絡：博達浩華國際財經傳訊集團電郵︰gench.hk@pordahavas.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SYDNEY, AU, Mar 28, 2026 - (ACN Newswire via SeaPRwire.com) - Vantage Goldfields Limited (Vantage Goldfields) owns Vantage Goldfields Pty Ltd (VGL), Barbrook Mines Pty Ltd (Barbrook) and Makonjwaan Imperial Mining Company (Pty) Ltd (MIMCO) (collectively the Vantage Companies), which own the Lily and Barbrook mines in South Africa. The Vantage Companies are currently in business rescue in South Africa, which is the legal process that assists financially distressed companies restructure, or otherwise avoid liquidation.An announcement was made on 26 March 2026 by TSX-V listed Lions Bay Capital Inc. (Lions Bay), which the Vantage Companies believe is misleading to investors and fails to disclose material information (the Announcement). That Announcement referred to Lions Bay receiving approval from a business rescue practitioner (BRP) of the Vantage Companies and calling a meeting of creditors to approve business rescue plans for the Vantage Companies.The Announcement is misleading and fails to disclose relevant material information regarding the Vantage Companies and Lions Bay proposal, including:While the Announcement referred to a Business Rescue Practitioner (BRP) (being Mr Devereux) approving the Lions Bay proposal, it failed to disclose that the Vantage Companies have two appointed BRPs and the second BRP has not approved the Lions Bay's proposal. Both BRPs have to approve a proposal in order for it to be presented to creditors. The second BRP was appointed by the Boards of the Vantage Companies, and his appointment was confirmed by the Companies and Intellectual Property Commission (CIPC), the corporate regulator in South Africa.The second BRP was appointed to ensure that all viable proposals for the rescue of the Vantage Companies are properly considered and that a business rescue is then properly and lawfully implemented for the benefit of all stakeholders, including creditors, former employees and the local community, as soon as possible.Vantage Goldfields as the owner of the Vantage Companies and Lily and Barbrook mines, has received a number of viable proposals for the rescue of the Vantage Companies and the reopening of those mines, which should be properly considered by the BRPs. These proposals should result in a better outcome for creditors and other stakeholders of the Vantage Companies than the Lions Bay proposal.Mr. Devereux acted unilaterally and unlawfully in purporting to approve an offer from Lions Bay and convene a meeting of creditors of the Vantage Companies. Vantage Goldfields believes that Mr. Devereux misled such creditors by failing to disclose that Lions Bay does not have the necessary US$40 million in funds to be able to complete its proposal.The Announcement failed to disclose that for the Lions Bay proposal to be able to be implemented, an approval from a BRP is not legally sufficient to be able to implement that proposal, and that proposal would need to be approved by specified majorities of creditors of each of the Vantage Companies. Vantage Goldfields has been informed by the largest secured creditor of the Vantage Companies that it does not support and will not vote in favour of the Lions Bay proposal at the necessary meetings of creditors, on its current terms and given that Lions Bay does not have all the necessary funds to complete the proposal. That creditor also has not agreed to release its securities over the asset of the Vantage Companies.Therefore, the necessary approvals of creditors will not be obtained, and the Lions Bay proposal will not be able to be implemented as currently proposed.Vantage Goldfields intends to ensure that all viable proposals are properly considered for the business rescue of the Vantage Companies, and that the business rescue process is progressed and implemented properly in accordance with South African law. Vantage Goldfields remains fully committed to reopening the Lily and Barbrook mines for the benefit of all creditors, former employees, affected persons and other stakeholders of the Vantage Companies.Stephen TurnerChairman-Vantage Goldfieldsst@stephenturner.com.auThis press release contains forward-looking statements, including statements about our future operations, plans, objectives, expectations, estimates, forecasts, or projections. Forward-looking statements are inherently subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause actual results, performance, or outcomes to differ materially from those expressed or implied.Under Australian law, statements about future matters must be based on reasonable grounds at the time they are made or they may be considered misleading. We believe the forward-looking statements in this release are based on reasonable grounds; however, events or circumstances may cause actual results to differ.These risks and uncertainties may include, among other things, changes in market conditions, economic factors, industry developments, operational challenges, regulatory changes, and other factors known or unknown to the company.Forward-looking statements speak only as of the date of this release, and except as required by law, the company undertakes no obligation to update or revise any forward-looking statements to reflect new information, future events, or changed circumstances.Source: Vantage Goldfields Limited Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - In the Hong Kong stock market, the key to consistently winning investor trust lies not just in periodic earnings growth, but in the ability to stably transform operating results into shareholder returns. According to the latest 2025 annual results report disclosed by Shoucheng Holdings (0697.HK), the company proposes a dividend of 780 million HKD, corresponding to an average annual market value dividend yield of approximately 5.6%. Looking at the long term, since its strategic transformation in 2018, the company has continuously advanced business transformation and structural optimization, leading to steady improvements in profitability and cash flow quality. It has maintained stable dividends for many consecutive years, with a cumulative dividend scale of approximately 6 billion HKD over eight years, shifting the investment logic from "growth expectations" toward "balancing both growth and returns".It is noteworthy that this dividend does not rely on high leverage or short-term overdrafts; rather, it is a proactive return built on improved balance sheets, enhanced operating quality, and optimized cash flow. As of December 31, 2025, the company's bank balances and cash stood at 3.671 billion HKD, with total borrowings of 979 million HKD. The cash-to-interest-bearing debt coverage ratio is approximately 3.75 times, demonstrating strong dividend sustainability and a significant financial safety margin.Over the past eight years, Shoucheng Holdings has gradually formed a smart infrastructure asset service system centered on parking asset management, industrial space management, REITs investment, and equity investment, constructing a composite model of "operational efficiency + asset management + capital circulation". Mature businesses such as parking and industrial parks continue to provide steady cash flow, serving as the practical foundation for the company's dividends. Meanwhile, REITs investments, the robotics ecosystem, and emerging industry funds further open up space for profit realization and valuation enhancement.Among these, the robotics business is becoming a significant incremental driver of Shoucheng Holdings' long-term value. In recent years, the company has continuously refined its robotics layout around "investment + operations + ecosystem," systematically investing in several leading robotics enterprises. Through scenario integration, channel construction, and industrial services, it has pushed projects from technical verification to commercial implementation. As relevant companies accelerate financing, see valuation increases, or move toward IPOs, the robotics segment is expected to continuously strengthen the company's mid-to-long-term profit release and shareholder return capabilities.Furthermore, in the latest Chairman's Statement, Chairman Zhao Tianyang explicitly expressed "gratitude" to investors and continued to emphasize "creating long-term value for investors". This statement is not merely a declaration of attitude but sends a clear signal: Shoucheng Holdings is placing shareholder returns and long-termism in a more prominent position. For the market, the significance of eight years of continuous dividends has long transcended a simple profit distribution; it serves as a more certain anchor of confidence for long-term capital amidst complex economic cycles. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 在港股市場中，真正能夠持續贏得投資人信任的，不只是階段性的業績增長，更是將經營成果穩定轉化為股東回報的能力 。根據首程控股(0697.HK)最新披露的2025年全年業績報告，公司擬分紅7.8億港元，對應年度平均市值派息率約5.6% 。若將時間拉長，自2018年戰略轉型以來，公司持續推進業務轉型與結構優化，盈利能力與現金流質量不斷提升，已連續多年保持穩定分紅，八年累計分紅規模約60億港元，投資邏輯正從「成長預期」進一步走向「成長與回報並重」 。值得關注的是，這一分紅並非依賴高槓桿或短期透支，而是建立在資產負債表改善、經營質量提升和現金流優化基礎上的主動回報 。截至2025年12月31日，公司銀行結餘及現金為36.71億港元，借款總額為9.79億港元，現金對有息負債覆蓋倍數約為3.75倍，顯示出較強的分紅可持續性和財務安全邊際 。過去八年，首程控股逐步形成以停車資產管理、產業空間管理、REITs投資與股權投資為核心的智能基礎設施資產服務體系，構建起「運營提效+資產管理+資本循環」的複合模式 。停車、園區等成熟業務持續提供穩健現金流，成為公司分紅的現實底盤；REITs投資、機器人生態及新興產業基金，則進一步打開了收益兌現與估值提升空間 。其中，機器人業務正成為首程控股未來長期價值的重要增量 。近年來，公司圍繞「投資+運營+生態」持續完善機器人佈局，系統投資多家頭部機器人企業，並通過場景導入、渠道建設和產業服務，推動項目由技術驗證走向商業落地 。隨著相關企業融資提速、估值提升乃至邁向IPO，機器人板塊有望持續增強公司中長期利潤釋放與股東回報能力 。更值得一提的是，在最新主席報告書中，主席趙天旸明確表達了對投資人的「感恩」，並繼續強調「為投資人創造長期價值」 。這一表述並非簡單態度宣示，更釋放出清晰信號：首程控股正把股東回報與長期主義放在更加重要的位置 。對市場而言，八年持續分紅的意義，也早已超越一次利潤分配本身，而是在複雜週期中，為長期資本提供更具確定性的信心錨點 。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, March 23, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines today announced that it has entered into an Asset Purchase Agreement with Corxel Pharmaceuticals Hong Kong Limited ("CORXEL"). Under the agreement, the Company has acquired the rights to develop, manufacture, and commercialize CARDAMYST™ (etripamil) nasal spray in Greater China, including Chinese Mainland, Hong Kong, Macao and Taiwan region.Under the terms of the agreement, Everest will pay CORXEL an upfront payment of US$30 million (equivalent to approximately RMB344,895,000), as well as potential development milestone payments of up to US$20 million (equivalent to approximately RMB137,958,000). As part of this agreement, Everest will be assigned and transferred rights, interests, claims, duties, obligations and liabilities (other than certain excluded liabilities) under the Milestone License Agreement entered into by CORXEL in May 2021 and certain related ancillary agreements.CARDAMYST™ (etripamil) nasal spray is a novel, rapid-acting calcium channel blocker as administered as needed via a convenient, portable nasal spray. It offers rapid onset of action, favorable tolerability, and the potential for at-home self-administration, enhancing patient accessibility. In December 2025, CARDAMYST was approved by the U.S. Food and Drug Administration (FDA), becoming the first and only self-administered nasal spray in more than 30 years capable of converting paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. As a rapid-acting treatment option, CARDAMYST can be self-administered outside the emergency department or other healthcare settings, enabling patients to actively manage episodes and gain greater control over their condition. In addition to its approved indication for PSVT, etripamil nasal spray is also under clinical development for atrial fibrillation with rapid ventricular response (AFib-RVR). Phase II trials have shown encouraging results, and Phase III trials are planned, with the potential to further extend its therapeutic impact to a broader patient population.In China, the New Drug Application (NDA) for etripamil nasal spray was accepted by the National Medical Products Administration (NMPA) on January 17, 2025 and is expected to receive approval in the third quarter of 2026.PSVT is characterized by abnormalities in the heart's electrical system that cause sudden unexpected and often severely symptomatic episodes of rapid heart rate. There are currently no approved self-administered, fast-acting, non-injectable therapies for acute PSVT, leaving patients with limited treatment options beyond emergency care. Approximately 2.3 to 4 per 1,000 individuals are affected by PSVT, representing an estimated 3 to 6 million patients in China.AFib-RVR is a type of irregular heart rhythm, characterized by an irregular and elevated heart rate. Its onset is typically gradual, episodes are less likely to terminate spontaneously, and the condition tends to recur, significantly increasing the risk of thromboembolism and serious complications such as stroke and heart failure. In China, atrial fibrillation affects an estimated 1.6% of the population, representing nearly 20 million patients, and is expected to increase with an aging population. Both PSVT and AFib-RVR are associated with a loss of control and a significant psychological burden for patients.Overall, the combined patient population for PSVT and AFib-RVR exceeds 25 million, representing a significantly unmet clinical need that urgently requires more convenient and more effective treatment options.In terms of clinical data, the NDA for etripamil nasal spray was accepted by the NMPA based on data from the pivotal global Phase 3 RAPID study and the China Phase 3 JX02002 study. Both trials met their primary endpoints. Overall, the treatment emergent adverse events (TEAEs) were comparable between the etripamil and placebo groups. The FDA approval of CARDAMYST was supported by a robust clinical program that included safety data from more than 1,800 participants across more than 2,000 PSVT episodes. This included the Phase 3 RAPID trial, a global, randomized, double-blind comparison of etripamil versus placebo, published in The Lancet in 2023. The RAPID trial achieved its primary endpoint, with 64% of participants who self-administered etripamil (N=99) converting from supraventricular tachycardia (SVT) to sinus rhythm within 30 minutes compared with 31% on placebo (N=85) (HR = 2.62; p<0.001). The median time to conversion was 17 minutes (95% CI: 13.4, 26.5) for etripamil versus 54 minutes (95% CI: 38.7, 87.3) for placebo. Etripamil nasal spray is also under clinical development for AFib-RVR. In the randomized, controlled Phase-2 ReVeRA study, etripamil demonstrated rapid and significant reduction in ventricular rate in patients with AFib-RVR, achieving its primary endpoint. A greater number of patients receiving etripamil achieved a ventricular rate of less than 100 bpm (58.3%) than those receiving placebo (4%). The safety profile was consistent with previous studies.From a strategic perspective, this transaction is also seen as an important step for the Company in implementing 2030 Strategy. Driven by its 2030 Strategy, and led by Mr. Yifang Wu, Chairman of the Board, Everest is accelerating growth through a dual-engine approach that combines strategic business development partnerships with in-house R&D. This transaction further strengthens Everest's expanding cardiovascular franchise, building on recent strategic initiatives and reinforcing the Company's disciplined approach to constructing focused therapeutic verticals with meaningful lifecycle expansion potential. Through continued advancement of its pipeline and product portfolio globally, Everest aims to deliver innovative therapies to more patients, create sustainable long-term value, and advance its position to become a leading global biopharmaceutical company."We are pleased to collaborate with CORXEL, this agreement marks an important step in our continued expansion in the cardiovascular field and a meaningful milestone in advancing our growth 2030 strategy," said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. "CARDAMYST is currently the only therapy designed for at-home self-administration to enable the acute termination of PSVT and AFib-RVR episodes, addressing a significant unmet medical need among patients in China. We will leverage our clinical development expertise and established commercialization platform to accelerate its advancement and future launch in Greater China, while further strengthening our cardiovascular franchise and unlocking its broader potential across atrial arrhythmias."As the registration and commercialization of Etripamil nasal spray progress, the company aims to further expand its cardiovascular portfolio. Leveraging its established clinical development and commercialization capabilities, Everest Medicines will accelerate the delivery of innovative assets, advance its 2030 strategy, and bring more treatment options to patients. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - As AI accelerates into the inference era, enterprise-grade AI is achieving large-scale deployment, driving an exponential surge in Token consumption and ushering data demand into a new development stage. Against this backdrop, high-quality, structured and scenario-specific professional data has become critical for enterprises to forge core strategic competitiveness in the era of AI.As a leading provider of AI real-time data infrastructure and analysis services in China, Xunce Technology is rapidly solidifying its core position in AI data, driven by industry tailwinds, full-chain technological capabilities and diversified growth engines. Amid the unfolding landscape of the intelligent economy, this ten-year industry stalwart is entering a pivotal window for structural revaluation.Token Value Restructuring: Making Every Data Access Quantifiable and MonetizableFounded in 2016, Xunce Technology has built a full-chain technological system spanning data acquisition, cleansing, standardization, real-time computing and large- model optimization over a decade of development. With AI Data Agent at its core, the Company specializes in millisecond-level real-time data processing, serving a diversified portfolio of industries including finance, urban governance, high-end manufacturing, healthcare, robotics, satellite applications, low-altitude economy, electric power, power grids and energy.As the era of AI inference unfolds, Token is evolving from mere “fuel” to a form of “hard currency”. Maximizing the value of each individual Token has emerged as a central challenge in the large-model inference era. Today, general-purpose large models typically rely on a “computing power for precision” approach, where every inference run generates substantial wasteful Token consumption. Should inference fail, all Tokens expended in the process are lost entirely, which is a common pain-point plaguing general AI systems.By contrast, vertical AI solutions equip general large language models with an external industry “brain” powered by domain-specific data. At its core, such solutions optimize inference logic via business-aware models, enabling upfront task feasibility validation and eliminating Token waste at the source. With deep expertise in professional vertical domain data modeling, Xunce Technology leverages its extensive portfolio of high-quality, scenario-specific proprietary data to act as an “efficiency multiplier” for every Token invocation. This structure translates Token consumption into higher-precision outputs while securing maximal result certainty. Crucially, the Company is developing full-chain capabilities spanning data metering, pricing and settlement, enabling quantifiable and monetizable measurement for every data access. By elevating per-unit Token efficiency, it delivers enhanced business value to enterprise clients.Aligned with this strategy, Xunce’s platform features a “LEGO-inspired” modular architecture, enabling clients to flexibly compose modules tailored to their specific needs. This “assemble-on-demand, adapt-in-real-time” design fosters deep and long-term customer stickiness. The Company also employs a highly flexible pricing framework, with fees structured around module count, processing throughput and other key metrics. Supported by subscription, transaction-based and Token-based payment models, its pricing mechanism precisely aligns with diverse client demands.Currently, Xunce Technology is fully building a full-chain data measurement and settlement system. It is exploring pricing mechanisms tied to large model inference frequency and module usage count, allowing customers to pay for effective Tokens rather than raw computing power consumption.Inflection Point Reached, Profitability ConfirmedDriven by Token value restructuring and innovative business models, Xunce Technology has delivered robust performance and reached a historic inflection point. In H2 2025, the Company posted an adjusted net profit of RMB 50 million, achieving its first positive profitability. Meanwhile, revenue rose from RMB 197.85 million in H1 2025 to RMB 1,086.81 million in H2, representing a 449.32% quarter-on-quarter surge. Amid rapid business expansion, the Company has witnessed a substantial improvement in profitability.Explosive Revenue GrowthReturn to Profit in H2Doubled ARPU & Per Capita GrowthImproved Cash Flow & Operating Metrics+103% Y/YNarrowed by 33%+105% Y/YSignificant Improvement2025 full-year revenue YoY growth2025 full-year adjusted net loss2025 ARPU YoY growth2025 net operating cash flow+449% H/HRMB 50 million+135% Y/YAmple cash on hand in 20252025 H2 revenue HoH growth2025 H2 adjusted net profit2025 per capita revenue YoY growthAverage collection period decreased in 2025For the full year, the Company posted total operating revenue of RMB 1,284.66 million, representing a substantial year-on-year increase of 103.28% and successfully breaking the key milestone of RMB 1 billion in revenue. This signifies that the Company has evolved from an early-stage, technology-driven startup into a new era of platform-based development with scalable and replicable business models.Furthermore, the Company’s combined gross proceeds for 2025 amounted to approximately RMB 792.08 million, representing a substantial increase of 63.44% compared to approximately RMB  484.63 million in the previous year. In terms of adjusted net loss, after deducting one-off non-recurring gains and losses, the Company’s adjusted net loss for 2025 was RMB 54.84 million, representing a significant narrowing of 33% from RMB 82.37 million in 2024.Notably, the Company achieved combined gross margin of 62% in 2025, exceeding that of Cambricon (55%), a leading AI chip provider, and far outpacing general large- model developer Minimax (25.4%). This underscores its high-value strategic positioning and resilient business model in the AI data infrastructure sector.In terms of R&D investment, Xunce Technology has also maintained efficient growth conversion. In 2025, the Company’s R&D expenditure reached RMB 450.44 million, with R&D expenses accounting for 48% of revenue, driving a 105% year-on-year increase in operating revenue. For comparison, Minimax’s R&D expenditure accounted for as high as 219% of its revenue, with a revenue growth rate of 159%. Xunce achieved a comparable expansion pace with a lower R&D intensity.As revenue scale continues to expand and gross margin in new industries gradually stabilize, the Company’s short-term objective is to achieve an inflection point in adjusted net profit. Looking ahead, as the industries already deployed enter a period of margin stabilization and Token-based payment and revenue-sharing models gain accelerated traction, its net profit is poised to improve at an accelerated rate.Driven by Diversified Growth Engines, Business Structure Continuously OptimizedThe robust revenue growth is not accidental, but underpinned by Xunce Technology’s multi-dimensional, systematically structured growth framework.Accelerate cross-industry replication. The Company currently covers 9 major industries, benchmarking Palantir’s 17 industries and leaving ample room for horizontal expansion. Xunce Technology is rapidly deepening its presence in key national strategic sectors such as asset management, telecommunications, electric power, urban management, high-end manufacturing, healthcare, energy, robotics training platforms and commercial aerospace. For each new industry, the Company first completes industry-specific data accumulation over 3 to 5 years, enabling rapid replication and scaled deployment across peer customers thereafter.The business model fosters deep customer value enhancement. As customers evolve from single-module adoption to multi-module deployment, and from pilot trials to full integration into core business workflows, substantial upside potential in ARPU remains. By synergistically lifting Token invocation volume, module usage count and per-Token value, the Company will unlock a new dimension of growth.Steadily expand overseas business and establish a global layout. The Company targets raising its overseas revenue share to 10% to 15% in 2026, and will further escalate its globalization strategy during 2027 and 2028, unlocking new avenues for sustained long-term growth.Cultivate a strategic cooperative ecosystem to forge deep integration with upstream and downstream partners in computing power and algorithms. Xunce Technology is engaging in in-depth collaboration with leading domestic GPU providers and large language model enterprises to build a one-stop solution encompassing “infrastructure computing power, upper-layer applications and data governance,” further solidifying its core position in the AI data infrastructure sector.      Pioneer cutting-edge applications to seize commanding heights in future industries. From robotics data platforms to commercial aerospace, low-altitude economy and power grid systems, Xunce Technology has taken the lead in extending AI infrastructure to emerging sectors with stringent demands for real-time performance and operational reliability. Such mission-critical scenarios with ultra-high requirements for data timeliness and stability serve as a rigorous validation of the Company’s technological advantages. The Company will continue to ramp up R&D investment in frontier fields, refine its technical capabilities through high-end application scenarios and unlock new high-growth, high-value growth tracks for long-term development.Evolving from Data Services to Core AI Economy Infrastructure: Building Sustainable Competitive BarriersFrom a macro perspective, the artificial intelligence data sector is witnessing a profound convergence of five defining trends: a surge in demand for real-time, secure, high-quality data in the era of AI Agent; the rise of domain-specific models elevating professional data as a critical enabler for industry-wide intelligent upgrading; standardization of data interfaces driven by next-generation AI operating systems including Open Claw, positioning Xunce Technology as a core data Token provider; Token-based payment emerging as a new paradigm for the data element market; and the implementation of data asset capitalization policies, spurring a sharp rise in enterprises’ mandatory investment in data governance.At the intersection of these five pivotal trends, Xunce Technology has established a robust fundamental logic for sustained long-term growth. The Company has evolved beyond a traditional data infrastructure provider to become a critical “connector” and “enabler” linking large models, computing power and cloud vendors. By integrating upstream models, downstream computing power and horizontal collaboration with cloud vendors, the Company delivers irreplaceable data-centric value to its enterprise clients.The Company stresses that it shares a natural upstream-downstream synergy with general large-model providers, rather than a competitive dynamic. Analogous to the deep collaboration between GPU manufacturers and model developers, the value of Xunce Technology lies in a mutually reinforcing cycle: the wider the adoption of models by its clients, the greater the opportunity for the Company to deliver services and generate incremental value for clients.Notably, in contrast to niche market players offering only isolated modules such as data cleansing or computing engines, Xunce Technology’s core differentiation lies in its full-process coverage and outcome-driven accountability. The Company provides an end-to-end solution spanning data acquisition, cleansing, standardization, modeling, real-time computing and model tuning, ensuring that final data delivered to clients is clean, accurate, real-time and accessible for model invocation at millisecond latency. Furthermore, through deep integration into clients’ private clouds or on-premises environments, the Company acts as a dedicated data steward, fostering exceptional customer stickiness and forging robust, sustainable competitive barriers.Currently, the Company’s product portfolio and solutions feature more than 300 functional modules, covering a full spectrum of scenarios from data infrastructure to upper-layer analytics applications. In 2025, its active paid clients base reached 230, with an outstanding customer retention rate of 90%. ARPU increased substantially from RMB 2.72 million in 2024 to RMB 5.59 million in 2025, representing a year-on-year growth of over 103%.As algorithms become increasingly open-source and computing power tends toward standardization, what truly sets companies apart lies in data — particularly industry data that has undergone sophisticated governance and can effectively empower large models. Backed by a decade of deep industry expertise, Xunce Technology has established a substantial and sustainable competitive barrier in this domain.ConclusionFrom an early-stage private equity tool provider to a cross-industry AI data infrastructure builder, and from a module supplier to a Token-priced core platform, Xunce Technology has remained committed to unlocking data as a scarce, strategic resource that is freely circulable, readily callable and empowered to drive high-quality decision-making.Amid the rapid emergence of new intelligent economic paradigms, the Company stands at the threshold of a fundamental structural revaluation, with the potential to enter the RMB 100-billion market cap camp. It is a competitor to none, but an indispensable partner to all. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - Analogue Holdings Limited (“Analogue” or the “Company”, together with its subsidiaries, the “Group”) (stock code: 1977), a leading provider of electrical and mechanical (“E&M”) engineering solutions, and information and communications technology services for smart cities, today announced its annual results for the year ended 31 December 2025 (“the Year” or “FY2025”) with net profit growth, contracts-in-hand achieving another record high and order intake more than doubled, providing a solid business foundation for the coming three years and beyond.Financial Highlights- Profit attributable to owners of the Company increased 23.5% to HK$167.0 million.- Contracts-in-hand surged 61.8% to HK$17,878.7 million, hitting another record-high, made possible by a 113.7% increase in order intake to HK$12,913.6 million during the Year.- The intake of new maintenance contracts for housing programmes, environmental projects and lifts and escalators increased 51.4% to HK$1,669 million, reinforcing the recurring revenue stream.- The Group maintained a strong cash position, with bank balances and cash of HK$1,020.8 million and gearing ratio reduced to 10.1% for FY2025 from 26.2%.- The Board has resolved to pay a second interim dividend of HK2.9 cents per share. Total dividend for the year amounted to HK5.5 cents per share with 25.6% increment year-on-year.Chairman Dr Mak Kin Wah said, “The Year 2025 saw profound changes around the world, with challenges and yet also opportunities. Our Group has continued to stride forward: upholding what we commit by delivering the fundamentals well, striving for continuous improvement to make transformation actionable, investing in technology advancement and productivity, and bringing Hong Kong’s engineering excellence to the world. We are pleased to report that the Group achieved profit growth, secured a record level of contracts-in-hand, and continued to build on our international market presence. These accomplishments highlight our distinctive comprehensive capability across diverse business segments, our commitment to excellence, and our leadership in advanced engineering techniques.”“Supported by strong cashflow, we are in a strong position to take on additional work where appropriate and to seize high-value opportunities as they arise. We will continue to stay agile and focused on capturing opportunities across our broad portfolio, build on our competitive strengths through continuous improvement, and reinforce the use of innovative solutions that enhance quality, safety and performance. We remain steadfast in our commitment to our customers, recognising that this is fundamental to earning their trust and cultivating enduring, strategic partnerships. Guided by our motto – ‘We Commit. We Perform. We Deliver’ – we will continue to maximise value for customers, shareholders, suppliers and stakeholders, while contributing to the communities we serve.”Business Review: Building Services- This segment remains the largest revenue contributor, with revenue reaching HK$3,279 million.- Contracts-in-hand reached a record-high level of HK$8,297 million with the total value of new contracts secured in FY2025 doubled to HK$6,470 million. The Group’s competitive edge in multidisciplinary packaged projects and its industry leadership in innovative MiMEP and other new engineering techniques helped it to secure major contracts.- With strategic investments to accelerate innovation and modern manufacturing facilities in Zhuhai and Hong Kong, the Group continues to lead in MiMEP and DfMA technologies.- Following the successful acquisition of a property management licence, the Group expanded its business to deliver integrated solutions across the entire building lifecycle. This new capability, spanning construction, maintenance, operations and long-term facility management, creates a potential revenue stream that complements core services.- Through continuous development of innovative technologies and operational optimisation, the segment is positioning itself to maintain the market competitiveness while exploring opportunities in other markets in Southeast Asia.Environmental Engineering- This segment achieved record-high contracts-in-hand and order intake, increasing 86.9% and 253.7% to HK$8,094 million and HK$5,355 million respectively. Segment revenue also increased by 18.0% year-on-year to HK$1,591 million.- The segment maintained active tendering throughout the period and was awarded significant contracts, including contracts of a record-breaking value to relocate sewage treatment works in Sha Tin to caverns, sewage pumping station at Ma On Shan and more.- Formed a joint venture company in Qingyang city to explore the operation and maintenance business in the Chinese Mainland.- Explored project opportunities in Asia and the Middle East and the expansion of its expert services into Europe.Information, Communications and Building Technologies (“ICBT”)- Segment revenue remained at HK$630 million. Contracts-in-hand totalled HK$852 million at the year end, and order intake was HK$523 million during the Year.- This segment continued to reinforce its leadership in green and intelligent building solutions under the DigiFusion brand, to enable the development of smarter, more sustainable urban environments.- Continued to leverage ATAL Tower as a platform for developing innovative technologies and broaden its technological capabilities through strategic collaborations with leading manufacturers in the Chinese Mainland and around the world, to strengthen its ability to deliver scalable, high-performance solutions across a wide range of sectors.Lifts and Escalators- Revenue and order intake increased 11.0% to HK$587 million and by 3.2% to HK$566 million respectively.- Transel Elevator & Electric Inc. (TEI), the associate company in the United States (US), secured a contract for the world-class vertical transportation system in the iconic 56-storey luxury hotel skyscraper on the border of Times Square in New York. TEI also further strengthened its market position by extending its footprint into the Southeastern part of US.- Actively built on its presence in the UK and broadened its network across other international markets, reinforcing its global ambitions in vertical transportation solutions.- Machine-Room-Less lift products continued to gain traction in key international markets- Streamlined the manufacturing processes of Nanjing factory, broadened its product portfolio and strengthened the overall product quality, aligning with the Group’s global vision and reaffirming its commitment to delivering reliable, high-performance vertical transportation solutions.For further details of the 2025 Annual Results, please refer to the announcement filed with The Stock Exchange of Hong Kong Limited.About Analogue Holdings LimitedEstablished in 1977, Analogue Holdings Limited is a leading provider of electrical and mechanical (“E&M”) engineering solutions and information and communications technology (“ICT”) services for smart cities, with headquarters in Hong Kong and operations in the Chinese Mainland, Macau, the United States, the United Kingdom, Germany, Singapore and Malaysia. Serving a wide spectrum of customers from public and private sectors, the Group provides multidisciplinary and comprehensive E&M engineering and technology services in four major segments, including Building Services, Environmental Engineering, Information, Communications and Building Technologies (“ICBT”) and Lifts & Escalators.The Group also manufactures and sells lifts and escalators internationally and has entered into an alliance with Transel Elevator & Electric Inc. (“TEI”), one of the largest independent lifts and escalators companies in New York, the United States. The Group’s associate partner, Nanjing Canatal Data-Centre Environmental Tech Co., Ltd. (603912.SS), specialises in manufacturing of precision air conditioners. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 領先的機電工程與智慧城市的資訊及通訊科技服務供應商安樂工程集團有限公司（「安樂工程」或「公司」，連同附屬公司統稱「集團」）（股份代號：1977），今天宣佈截至2025年12月31日止年度（「年內」或「2025財政年度」）的全年業績，除淨利潤錄得增長，集團的手頭合約更再創新高，訂單額增長逾倍，為未來三年及往後的發展奠下穩固基礎。財務摘要- 本公司擁有人應佔溢利按年增23.5%至1.670億港元- 手頭合約增61.8%至178.787億港元，再創歷史新高，受惠於年内訂單額增長113.7%至129.136億港元- 新增維修保養合約涵蓋房屋項目、環保項目以及升降機及自動梯，合約額增51.4%至16.69億港元，鞏固經常性收入來源- 集團維持強健現金水平，銀行結餘及現金為10.208億港元，資產負債比率則由26.2%降低至2025財政年度的10.1%- 董事會已決議派付第二次中期股息每股2.9港仙；全年合共派息每股5.5港仙，較上年度増25.6%主席麥建華博士表示：「2025年見證了全球的重大變化，挑戰與機遇並存。集團穩步向前，以謹慎履行承諾作堅實基礎，不斷精益求精，更推動革新落到實處、投資提升技術及生產力，引領香港工程的卓越實力踏上環球市場。我們欣然宣布，集團實現了利潤增長，更創下歷史新高的手頭合約水平，並持續鞏固在國際市場的影響力。這些成就彰顯了我們在各個業務領域的綜合能力，對卓越品質的承諾，以及在先進工程技術方面的領導地位。」「憑著充裕的現金流支持，我們具實力適時開展更多工程項目，並在高價值商機出現時抓緊機會。我們將繼續保持靈活專注，積極把握集團廣泛業務組合中的機遇，透過持續提升我們具競爭力的優勢，並強化應用創新解決方案，以提升工程品質、安全和表現。我們深知為客戶堅定不移地履行承諾，是贏得他們信任及維繫持久夥伴關係的基礎。秉持『重承諾、慎履行、獻成果』的座右銘，我們將繼續為客戶、股東、供應商和其他持份者創造最高利益，同時為我們所服務的社區作出貢獻。」業務回顧：屋宇裝備工程- 此業務板塊繼續成為集團最大的收益來源，收益達32.79億港元。- 手頭合約創下歷史新高，達82.97億港元，於2025財政年度新簽合約增長一倍達64.70億港元。集團在跨多專業的綜合項目中擁有競爭優勢，並有賴在創新的機電裝備合成法和其他新工程技術方面的領導地位成功取得重要合約。- 憑藉策略性投資以加快創新，並在珠海和香港發展現代化製造設施，集團得以在機電裝備合成法和裝配式設計技術方面繼續領先同儕。- 集團通過成功取得物業管理牌照擴大業務以提供可橫跨整個建築週期的綜合解決方案。此涵蓋建造、維修保養、營運，以至長期的設施管理的新能力，開拓了潛在的收益來源，與核心服務互補優勢。- 透過不斷開發創新技術和優化營運，此業務板塊強化自身定位以維持在市場中的競爭優勢，同時探索東南亞其他市場的發展機遇。環境工程- 此業務板塊的手頭合約與新增訂單額創下歷史新高，分別按年增加86.9%及253.7%至80.94億港元及53.55億港元。同時，業務收益按年增加18.0%至15.91億港元。- 此業務板塊於年內維持積極參與投標，並成功贏得標誌性合約，包括合約額破紀錄的搬遷沙田污水處理廠往岩洞、馬鞍山污水泵房等工程項目。- 於慶陽市開立了合營企業，以拓展中國內地的營運及維修業務。- 探索在亞洲和中東地區的項目機遇，並將專業服務拓展至歐洲市場。資訊、通訊及屋宇科技（「ICBT」）- 業務收益維持在6.30億港元，手頭合約價值截至2025年末為8.52億港元，年內新增訂單額為5.23億港元。- 此業務板塊持續以DigiFusion品牌鞏固其在綠色及智慧屋宇解決方案的領導地位，有助打造更智慧化、更可持續的城市環境。- 持續憑藉安樂工程大廈作為平台以研發創新技術，並透過與中國內地及環球領先生產商的策略合作持續擴大技術能力，從而加強在多個範疇的能力以提供可擴大規模的高效解決方案。升降機及自動梯- 收益與新增訂單額分別按年增加11.0%至5.87億港元，以及增加3.2%至5.66億港元。- 集團位於美國的聯營公司Transel Elevator & Electric Inc （「TEI」）取得重大合約，在聳立於紐約時代廣場旁的地標性56層摩天豪華酒店內提供世界級垂直運輸系統。TEI亦將業務版圖拓展至美國東南部，進一步鞏固其市場地位。- 積極加強在英國的業務，並擴大在其他國際市場的網絡，強化在垂直運輸解決方案領域的全球發展的雄心。- 無機房升降機產品繼續在主要國際市場取得進展。- 南京工廠簡化了生產流程，擴大產品種類，並提高了整體產品質量。這些提升正好配合集團的環球視野，肯定其承諾，矢志提供可靠和高效的垂直運輸解決方案。有關2025年度業績詳情，請參閱已呈交香港聯合交易所有限公司的公告。關於安樂工程集團有限公司安樂工程集團有限公司成立於1977年，為領先的機電工程與智慧城市的資訊及通訊科技服務供應商，總部設於香港，業務遍及中國內地、澳門、美國、英國、德國、新加坡及馬來西亞。本集團為公共和私營機構提供跨專業綜合機電及技術服務，涵蓋屋宇裝備工程、環境工程、資訊、通訊及屋宇科技（「ICBT」），以及升降機及自動梯等四大業務板塊。本集團同時製造及向全球銷售升降機及自動梯，並與美國紐約最大獨立升降機及自動梯公司之一 – Transel Elevator & Electric Inc.（「TEI」）達成夥伴關係。本集團的聯營公司南京佳力圖機房環境技術股份有限公司（603912.SS）專門製造精密空調設備。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 3月26日，海天味業（A股：603288；H股：03288）發佈2025年年度業績報告，面對2025年複雜多變的市場環境，憑藉多元產品矩陣、高效運營體系、硬核科技創新，公司在行業變革浪潮中穩健前行，交出一份彰顯行業龍頭實力與高品質發展成色的優異答卷。財報資料顯示，2025年公司核心經營指標穩健增長，實現營業收入288.73億元，同比增長 7.32%。盈利能力同步提升，全年歸母淨利潤70.38億元，同比增長10.95 %；扣非歸母淨利潤68.45億元，同比增長12.81%；調味品主業毛利率41.78%，同比增加3.15個百分點；各項經營資料均創下歷史新高，盈利品質與增長動力雙雙亮眼，彰顯公司硬核實力。豐富的國民產品矩陣，構築多元增長格局豐富完善的國民級產品矩陣，是海天味業實現穩健增長的核心基石。在產品矩陣方面，海天圍繞用戶需求持續推進品類創新，構建起覆蓋全場景烹飪的一站式產品體系，全方位滿足不同消費群體的多樣化需求。得益于豐富的產品矩陣與優異的產品品質，2025年，公司醬油、蠔油、調味醬等核心品類保持穩健發展，分別實現營業收入149.34億元、48.68億元及29.17億元，同比增長8.55%、5.48%及9.29%，構成業務增長的“金字塔基座”。其中，海天醬油產銷量和市場佔有率已連續數十年位居全國第一，海天蠔油的市場佔有率也連續10年位居全國第一，憑藉優質口感與穩定品質，成為千萬家庭與餐飲機構的首選；公司調味醬已形成產品豐富、風味立體、場景多元的產品體系，涵蓋黃豆醬、香辣醬等具備廣泛消費基礎的大單品，同時亦有柱侯醬、海鮮醬、拌飯醬、香菇醬等適用不同烹飪方式的特色醬料，紫蘇醬、桂林風味辣椒醬等適合不同地域口味的風味醬料，以及蔥油拌麵醬、重慶小面調料等便捷化調味醬，有效滿足用戶需求。此外，為順應消費者對醋類產品的細分化需求，公司堅持「傳統醋+特色醋」的產品佈局，同時不斷推陳出新，推出有機醋、果醋等多元化產品，形成豐富多元的醋類產品體系，進一步彌補品類空白，擴大市場覆蓋面。截至2025年底，公司擁有7個十億級以上產品系列、超30個億級以上產品系列，產品矩陣的豐富度與完整性持續提升。其中，金標生抽、草菇老抽兩大產品系列已暢銷60餘年，味極鮮醬油、海天上等蠔油兩大產品系列連續10餘年實現單品年收入超10億元，成為支撐公司業績穩健增長的「壓艙石」，其市場認可度與用戶忠誠度持續處於行業領先水準。在保持核心品類穩健增長的同時，海天精准把握消費趨勢變化，持續培育新興增長點，不斷豐富產品矩陣的層次與內涵。報告期內，在領先行業的產品力支撐下，以有機和薄鹽為代表的營養健康系列產品實現營業收入同比增速達48.3%，成為拉動業績增長的新引擎；食醋和料酒業務持續發力，規模優勢和體系化能力逐步顯現，市場佔有率穩步提升，為公司長遠發展注入強勁新動能。​值得關注的是，依託供應鏈規模效應、技術研發與柔性生產三大核心壁壘，海天加速從“調味產品供應商”向“一站式風味解決方案提供商”轉型，深度佈局商用市場，實現To C與To B業務雙輪驅動。截至2025年底，公司已為眾多餐飲連鎖、食品工廠及全球頭部零售品牌提供商用調味品一站式解決方案，成為公司業績增長的重要支撐。堅持以用戶為中心，全域深耕驅動效率與價值雙升堅持以用戶為中心，持續優化運營效率與用戶價值，是海天味業保持行業領先地位的關鍵所在。面對消費渠道的多元化變革，海天立足用戶需求，通過數字化賦能傳統渠道、擁抱新興渠道建設、聯動餐飲及工業渠道，實現效率與價值的雙重躍升，進一步鞏固市場滲透率。在傳統渠道方面，海天依託覆蓋全國的終端網路，借助數字化行銷工具和服務模式創新，持續向下沉市場滲透，並延伸到最終用家和消費者，顯著提高了終端覆蓋品質與消費者觸達效率，同時，通過終端管理的精細化升級，讓存量網點煥發新活力。2025年線下渠道營業收入達257.60億元，同比增長7.85%。線上與即時零售等新興陣地，海天主動適應消費場景的變化，通過規範銷售秩序、強化專業運營，實現新興渠道的高品質發展；針對新興渠道的消費特性，公司還推出線上定制化產品，精准匹配消費群體的需求，逐步構建線上與線下協同互促的健康發展模式，2025年線上渠道增幅高達31.87%。在商用渠道方面，依託柔性供應鏈與「銷研產一體化」快速回應機制，海天為餐飲連鎖和食品工廠提供從通用產品到定制化的一站式調味解決方案，實現「3天打樣、15天交付」的高效回應，大幅提升了客戶體驗與合作粘性。目前，餐飲與工業渠道穩健發展，收入占比持續提升，正成長為公司專業增長的重要動力源，進一步拓寬了公司的增長空間。堅持科技立企與創新，驅動價值鏈全面升級堅持科技立企、創新驅動，是海天味業實現高品質發展的核心動力。作為調味品行業數字化轉型的先行者，公司全面擁抱AI時代，推動人工智能、大數據與傳統釀造技藝深度融合，在守護匠心工藝的同時實現提質增效，推動行業從「傳統釀造」向「智慧釀造」轉型升級。海天味業堅持每年將研發投入保持在營業收入約3%的水準，近十年研發投入累計超65億元，累計擁有各類專利超1,000項，形成了完善的研發體系與創新機制。2025年1月，海天高明生產基地獲得全球醬油釀造行業首家「燈塔工廠」認證，標誌著公司數字化轉型已躋身全球行業標杆，也印證了中國調味品企業在智慧製造領域的領先實力。此外，公司部署端到端供應鏈創新用例，將AI與大數據深度應用於研、產、供、銷各環節，實現全鏈條的數字化、智慧化升級。在數字化全面賦能下，海天供應鏈運營效率顯著提升，訂單準時足額交付率（OTIF）不斷提高，綜合成本穩步下降，充分彰顯智慧製造帶來的效率紅利與競爭優勢。受益於在數字化轉型與高品質發展方面的突出成就，海天味業屢獲殊榮。2025年，公司斬獲「CGF中國供應鏈數字化與可持續韌性發展案例」「全國製造業數字化轉型典型案例」等多項殊榮，得到行業與社會的廣泛認可。同時，由海天主導起草的國家標準《食品數字化工廠通用技術要求》正式發佈，填補了國內食品行業數字化工廠通用技術標準的空白，為食品行業數智化升級提供「海天範式」，充分彰顯了公司的行業帶動力與責任擔當。回望2025年，海天味業以穩健業績、多元佈局、硬核實力，在高品質發展之路上行穩致遠，進一步鞏固了行業龍頭地位。展望未來，公司將繼續堅守匠心、深耕主業，持續優化產品矩陣、深化科技賦能、拓展全球市場，以更優質的產品、更高效的服務、更強勁的創新力，守護中國味道、引領行業升級，書寫中國調味品企業全球化高品質發展的嶄新篇章。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 3月27日，美麗田園醫療健康（02373.HK）正式發佈2025年度業績報告。年內，集團營收、利潤、現金流全方位高質量增長，以硬核業績凸顯行業龍頭的強增長韌性。集團盈利能力實現跨越式躍升。2025年，美麗田園集團總收入30億元，同比增長16.7%；毛利率提升至49.1%，同比提高2.8個百分點；經調淨利潤攀升至3.8億元，同比大幅增長41.0%，經調整淨利率達12.7%，提高2.2個百分點，盈利水平邁上新台階。公司持續顯現「現金牛屬性」。2025年集團經營活動產生的現金流量淨額達10.0億元，同比大幅增長25.4%；截至2025年12月31日，集團現金及類現金項目金額合計高達25.9億元，同比淨增41.6%，充沛且強勁的現金流為集團戰略投資與股東回報提供充足動能。這份營收與利潤大幅增長的亮眼業績，是集團「內生增長+外延並購」商業模式的成功體現，也是集團精益管理、提質增效及數智化賦能帶動整體效率提升的有力印證。「雙美+雙保健」模式賦能，盈利能力全面上揚作為核心基石業務，集團美與健康板塊逆勢高增，全年交出令市場矚目的亮眼答卷。2025年，美容和保健服務收入16.6億元，同比增長14.9%；毛利率提升1.2個百分點至41.9%；直營門店客流達172.4萬人次，同比增長23.2%；直營活躍會員增至14.6萬名，同比增長11.8%，直營活躍會員年均消費金額9738元，同比提升320元。直營活躍會員規模與年均消費實現雙增長。業績高質量增長的同時，集團錨定長期發展戰略。2025年，我們正式發佈超級供應鏈戰略，全面升級產品創研體系。未來，產品創研方式將全新拓展為全球精選、國際品牌合作、國際頂尖實驗室聯合研發三大模式並進，在傳承卓越品質的同時，注入創新動能。2026年2月，我們重磅宣佈與全球知名護膚品牌資生堂達成重磅戰略合作，在品牌影響力、服務體驗、科研共創等多維度深度攜手，開啟美與健康領域合作的新篇章。消費醫療兼具醫療價值屬性與消費彈性，是承載長期結構性機遇的優質賽道。美麗田園集團深耕消費醫療賽道，圍繞高端女性美與健康的核心醫療需求深度延伸佈局。過去16年，我們從0到1自建消費醫療能力，目前全國落地38家消費醫療機構，形成規模化佈局。2025年，消費醫療板塊整體收入13.4億，同比增長18.9%，占收入比例達到44.8%，成為重要的增長驅動力。具體來看，2025年集團醫療美容服務-秀可兒醫美逆勢增長，實現收入10.2億元，同比增長9.6%，毛利率大幅提升3.6個百分點至55.9%；客流10.2萬人次，同比增長13.1%，活躍會員攀升至3.6萬名，同比增長7.7%；活躍會員年均消費27,862元，同比增加490元。為進一步破局行業競爭、打造差異化核心優勢，秀可兒醫美精准錨定「專研抗衰」賽道，以「專家、專研、專注原生美」為品牌定位。2026年3月，Cellcare秀可兒品牌舉辦「專研抗衰」品牌升級發佈會，圍繞不同年齡層女性抗衰需求，打造 「初老抗衰、凍齡抗衰、逆齡抗衰」 的全週期產品藍圖，正式開啟秀可兒專研抗衰新時代。亞健康醫療服務--研源醫療作為集團增值業務迎來爆發式增長。2025年，研源醫療收入3.3億元，同比大增62.2%，收入佔比首次突破10%，成為集團業績增長的重要引擎；毛利率升至64.3%，同比提升6.1個百分點；客流量3.7萬人次，同比增長35.7%，活躍會員人數同比大增37.9%，活躍會員年平均消費28,032元，同比增加6287元。2025年，研源醫療旗下功能醫學板塊收入同比增長101%。在AI浪潮之下，我們將通過自研AI模型，深度融合精准檢測數據、專家診療路徑與臨床案例，實現「千人千面」的個性化診療方案與7x24全天候服務，以科技賦能醫療服務全面升級。研源醫療旗下女性特護板塊收入增長64%。我們將持續拓展服務版圖，構建「預防-治療-抗衰」女性健康醫療服務。並購整合戰略升級，以共贏之姿賦能行業發展中國「美與健康」市場坐擁萬億賽道規模，機遇與挑戰並存，合作共贏已經成為行業發展的必然趨勢。美麗田園主動投身行業整合進程，將投資並購上升為集團級核心戰略，以開放共贏的姿態攜手行業夥伴，共同推動美業高質量發展。2026年3月，集團重磅舉辦「尋找100位美業同行者」戰略投資暨行業賦能發佈會，宣佈將聚焦中國20個高線城市的美與健康服務機構，誠邀更多行業夥伴融入美麗田園生態體系，依託持續打磨精進的商業系統為行業夥伴提供全方位賦能提效，實現共生共贏。這一戰略佈局的底氣，源自集團過往逾30多起收並購項目中所積澱的深厚實戰經驗與可複製的整合方法論。2024年，集團完成對中國美容行業市占率第二大品牌奈瑞兒的收購，並通過系統化、精細化整合，實現奈瑞兒收入和利潤雙提升。2025年，奈瑞兒單店收入從收購前的575萬提升至810萬、經調淨利率從6.5%大幅提升至10.5%，以亮眼的數據印證了美麗田園強大的並購整合能力，更形成了一套可複製、可延展的行業整合成功範式。2025年10月，美麗田園集團宣佈以12.5億元人民幣全資收購行業第三大品牌思妍麗100%股權。伴隨著思妍麗於2026年1月正式併入集團報表，我們將複製奈瑞兒成功經驗，充分發揮自身模式優勢和平台能力，為業績增長注入新動能。至此，三大品牌齊聚美麗田園集團麾下，市場佔有率實現跨越式提升，中國美容行業競爭格局重塑。重磅打造商業系統，構建企業可持續增長核心壁壘33 年深耕，美麗田園集團從美容服務逐步延伸至消費醫療，已成功建成面向高線城市女性的美與健康綜合服務平台。2025年，集團重磅打造美麗田園商業系統，從多維度構建企業可持續增長模式，為長遠發展築牢體系根基。客戶價值成長系統。通過精細化客戶運營體系，我們構建起覆蓋推廣、獲客、轉化、會員留存、價值提升、複購、裂變的全鏈路運營閉環，為客戶持續創造長期價值。強平台+多品牌系統。我們構建了「強平台+多品牌事業部」協同的組織體系，支撐多品牌、多業務高效聯動與協同發展。前台事業部聚焦市場與客戶，靈活作戰、快速響應；平台沉澱能力、輸出標準，讓協同貫穿業務全流程，有效提升運營效率與業務延展性，為多品牌有序擴張提供堅實組織支撐。並購價值成長系統。我們構建了「投資+整合+成長」全週期並購價值成長體系，通過持續積累行業獨特的投資數據、成熟的投前模型、精進的投中整合，全面提升投後價值，形成成熟的並購與賦能機制，可適配不同規模、不同業務的優質標的，真正實現「並購即融合、融合即增值」。數智化與AI系統。集團將構建數智化驅動的管理體系，深度賦能美麗田園商業系統，讓體系能力可落地、可複製、可迭代，成為集團穿越經濟週期、持續引領行業發展的堅實支柱。資本市場價值提升，持續釋放長期投資價值2025年3月，集團正式發佈三大舉措，圍繞股東結構優化、高分紅比例及管理層激勵，持續向資本市場釋放長期投資價值。股東結構優化方面，2025 年 8 月，原PE股東中信產業基金正式退出主要股東行列，同步引入優質長期戰略投資者，股東結構進一步夯實。分紅方面，2026年董事會提議延續高分紅比例，將2025年歸母淨利潤的50%用於分紅，派發每股0.72港元，同比增長38.5%，以真金白銀的回報持續強化股東回報，彰顯企業對自身發展的堅定信心。管理層激勵方面，2025年，集團將未來三年收入及利潤目標與股權激勵深度綁定，首年業績目標已超額達成，激勵機制的有效性得到充分驗證。在此基礎上，公司進一步上調管理層股權激勵對應的三年業績目標，以更高標準統一公司與股東利益，在釋放增長潛力的同時，為投資者創造長期穩定回報。2025 年 11 月，公司成功納入 MSCI 全球小型股指數，進一步進入全球被動及主動型基金視野，吸引更廣泛的國際投資者關注。未來展望：三大超級戰略領航，錨定長期高質量發展美麗田園集團的長期願景是成為中國美與健康的領航者。站在行業整合與品牌升級的新起點，2025年11月，美麗田園正式發佈超級品牌、超級連鎖、超級數字化三大戰略，為未來高質量發展指明方向，擘畫長期發展藍圖。超級品牌，構建美與健康品牌矩陣。我們持續升級專業實力，打造超越客戶期待的體驗，重塑美容行業價值新空間。同時，積極參與並推動行業標準制定，將美麗田園的高標準上升為行業共識，提升消費者信任與品牌價值。超級連鎖，我們將發揮「雙美+雙保健」商業模式優勢，通過內生增長與外延並購雙輪驅動戰略帶動公司價值躍升。我們致力於打造20個收入過億的核心城市，同時構建自有供應鏈能力，融合全球精選與聯合專研，為中國高線城市女性提供兼具專業性、個性化、高品質的美容和消費醫療產品與服務。超級數字化，我們致力於打造數智化與AI系統基礎建設，構建數智化驅動的企業管理體系，打造數智引領的美與健康服務連鎖標杆企業。結語未來，美麗田園將繼續堅守「以客戶為中心」的初心，依託「美麗田園商業系統」，以「三大超級戰略」為指引，在不斷滿足高線城市女性對美與健康的多元需求的同時實現立體增長，推動中國美與健康行業的高質量發展。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

RESULTS HIGHLIGHTS:- The Revenue for the year ended 31 December 2025 was approximately HK$3,736.5 million, representing an increase of approximately 11.1% as compared with the same period last year.- The Gross Profit Margin for the year ended 31 December 2025 was approximately 55.8%; the gross profit was approximately HK$2,085.0 million, representing an increase of approximately 15.9% as compared with the same period last year.- The Group’s EBITDA for the year ended 31 December 2025 was approximately HK$938.1 million, representing an increase of approximately 32.4% as compared with the same period last year.- The Group’s net profit for the year ended 31 December 2025 was approximately HK$601.2 million, representing an increase of approximately 47.7% as compared with the same period last year.- Basic earnings per share for the year ended 31 December 2025 amounted to approximately HK63.7 cents, representing an increase of approximately 47.5% as compared with the same period last year.- The Board recommended the payment of a final dividend of HK15.0 cents per ordinary share for the year ended 31 December 2025.- For the year ended 31 December 2025, the Group recorded approximately 1,039,000 cases digital solution cases produced from the Group’s production facilities in Mainland China, Thailand and Vietnam, reflecting an increase of 32.7% as compared with the same period in 2024 as a result of our clients’ continued adoption of intra-oral scanners.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - 26 March 2026, Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic device provider, announces its annual results for the year ended 31 December 2025 (“the year”).During the year ended 31 December 2025, the Group’s multi-dimensional strategies and continuous enhancement of operational efficiency and productivity as supported by the ongoing trend of digitalization in the dental industry have resulted in the Group reporting record revenues, net profit and EBITDA numbers during this period. This occurred in a period of challenging macro-economic environment with general softness in demand for dental procedures and trade war uncertainties. The Group has been proactive in its approach to deal with the unprecedented international trade environment leveraging its international production facilities located in Thailand, Vietnam and Mainland China.The global digitalization trend continues to drive consolidation within the dental prosthetics industry, enabling the Group to further expand its market share. Our ongoing digital transformation initiatives are enhancing both customer and patient experiences while improving operational efficiency, further differentiating the Group from competitors and positioning us to outperform industry peers. The Group’s underlying fundamentals remain solid, and we are well positioned to capitalize on emerging opportunities going forward.European BusinessesDuring the year ended 31 December 2025, the European market recorded a revenue of approximately HK$1,887.0 million, representing an increase of approximately HK$268.0 million as compared with the year ended 31 December 2024. This geographic market accounted for 50.5% of the Group’s total revenue. The increase of revenue from the European market was mainly attributable to the increase in sales order volume driven by the launch of new products, such as digital dentures, and our state-of-the-art digital workflows.The Group has been the frontrunner to provide comprehensive digital solutions offerings, ranging from numerous minimal invasive and aesthetic prosthetic solutions to intra-oral scanners and clear aligners, and is well positioned to capture the opportunities arising from the accelerated digitalization trend of the dental industry. The Group continues to aggressively gain market share from international and domestic competitors through our established dental ecosystem solutions with a focus on education and digitalization, which is available within close proximity to our clients; effectively meeting our clients’ high expectations through our various onshore and offshore resources. The Group is committed and will continue to equip ourselves to provide the state-of-the-art digital solutions offerings to the dental community in the market.North American BusinessesDuring the year ended 31 December 2025, the North American market recorded a revenue of approximately HK$696.4 million, representing a decrease of approximately HK$55.7 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 18.6% of the Group’s total revenue.A significant portion of our business in the North America region comprises higher-end products manufactured domestically by MicroDental Laboratories, Inc. and its subsidiaries (“MicroDental Group”). While demand for discretionary cosmetic treatments remained soft throughout 2025, our centralized digital workflows and network-wide production oversight enabled us to deliver enhanced service quality and operational efficiencies to our North American customers.Our diversified supply bases in the US, China, Vietnam and Thailand continue to provide greater flexibility to navigate US tariff uncertainties — an advantage that sets us apart from competitors. Although digitalization of imported product lines drove growth in mass market cases, implementation of the US tariff in April 2025 introduced new uncertainties and contributed to a slow growth in sales for our import-focused business unit.Greater China BusinessesFor the year ended 31 December 2025, the Greater China market recorded a revenue of approximately HK$615.4 million, representing a decrease of approximately HK$46.8 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 16.5% of the Group’s total revenue.The Mainland China market faced headwinds from the volume-based procurement policies and a prolonged period of intense price competition and the situation started to stabilize in the second half of 2025. This also led to aggressive promotions for dental implant treatments by Mainland China dental clinics in Hong Kong (which experienced a notable decrease in patient visits in Hong Kong). The Group’s has deliberately pivoted away from low-margin segments and stay focused on serving mid- and high-value customers, ensuring long-term sustainable profitability of the Group’s business.The Group is optimistic in its mid/long-term outlook for this market in particular where the latest procurement-related government measures are expected to (i) standardize the pricing of dental prosthetics and develop price transparency, which would level the playing field; (ii) allow the Group’s leading brand name and reputation to be a key consideration for its client and customer; and (iii) have the Group benefit from its large production team and its ability to allocate resources efficiently according to the customer or client.Australian BusinessesFor the year ended 31 December 2025, the Australian market recorded a revenue of approximately HK$289.1 million, representing an increase of approximately HK$24.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 7.7% of the Group’s total revenue. The increase in revenue from Australia reflected a strong uptake of new digital products driven by the digitalization trend in dental industry and the revenue contribution from the acquisition of Digital Sleep which is partially offset by the depreciation of AUD against HK$ by 2.4% compared with the year ended 31 December 2024.Through our various brands, which offer onshore-and offshore-made products, at multiple price points ranging from economy and standard to premium/boutique, the Group is able to effectively penetrate the entire Australian market. We have invested in local production capacity to provide faster service to our customers, and to provide choices around where the products are made. The Group is one of the largest players in the Australian market and is a preferred supplier to the major corporate dental groups in the market.Other MarketsOther markets primarily include Thailand, Indian Ocean countries, Malaysia, Taiwan and Singapore. For the year ended 31 December 2025, these markets recorded a revenue of approximately HK$248.9 million, representing an increase of approximately HK$182.4 million as compared with the year ended 31 December 2024. This geographic market accounted for approximately 6.7% of the Group’s total revenue. The increase in revenue from Other markets was primarily driven by the revenue contribution from the newly acquired Hexa Ceram.Future Prospects and StrategiesThe global macroeconomic environment remains uncertain, with geopolitical tensions and potential tariff changes continuing to create headwinds. However, the Group’s geographically diversified production footprint and global distribution network position us strongly to navigate these challenges. Unlike many competitors reliant on single-country manufacturing, our operations across China, Vietnam and Thailand (including the newly acquired Hexa Ceram) provide superior resilience and flexibility. This strategy, combined with our ability to adapt quickly to local market conditions, enables the Group to mitigate risks and capitalize on opportunities across regions.The dental industry has continued to demonstrate remarkable resilience, underpinned by irreversible demographic trends, including aging populations and increasing awareness of oral health, which drive consistent long-term demand. Building on our record 2025 performance, the Group is well placed to sustain momentum and further strengthen its market leadership.Digitalization remains an irreversible industry trend that is accelerating consolidation of the dental prosthetics industry. We are at the forefront of this transformation, with digital solution cases now representing approximately 35–40% of total volume. Our centralized digital workflows, intra-oral scanner partnerships, proprietary solutions and global education centers have enhanced operational efficiency, reduced turnaround times and delivered superior customer experiences. These initiatives create high entry barriers and will continue to drive margin expansion and market share gains in the coming years.Following the successful integration of Hexa Ceram (Thailand’s largest dental laboratory, acquired in January 2025) and Digital Sleep Design (Proprietary nylon oral appliance to treat obstructive sleep apnea), our Southeast Asian presence and specialized capabilities have been significantly strengthened. This expansion, coupled with our diversified supply bases in the US, China, Vietnam, and Thailand, provides enhanced flexibility to address potential trade and geopolitical risks while supporting faster regional delivery.Looking ahead, the Group remains committed to reinforcing its worldwide leading position through a multi-dimensional approach. We will continue to pursue selective acquisitions, joint ventures and partnerships to expand and complement our product offerings, particularly in our high-growth clear aligner, Trioclear, while strengthening our distribution and sales networks. Ongoing investments in mass-scale production facilities, AI, automation, research and development, and digital innovation will drive efficiency gains and secure our position at the forefront of the industry.About Modern Dental GroupModern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices. Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 35,000 customers. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

業績摘要：- 截至2025年12月31日止年度收益約為37.4億港元, 同比增加約11.1%。- 截至2025年12月31日止年度毛利率約為55.8% ；毛利約為20.8億港元，同比增加約15.9%。- 截至2025年12月31日止EBITDA 約為9.4億港元，同比增加約32.4%。- 本集團於截至2025年12月31日止純利約為6.0億港元，同比增加47.7%。- 截至2025年12月31日止每股基本盈利約為63.7港仙，相較去年同期增加約47.5%。- 董事會建議宣派截至 2025年12月31日止年度末期股息每股普通股15.0港仙。- 截至2025年12月31日止年度，本集團於中國內地、泰國及越南生產設施生產之數碼化解決方案個案增加至約1,039,000件，較2024年同期增加32.7%，原因為更多客戶採用口腔內部掃描器。香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 2026年3月26日，全球領先之義齒器材供應商 - 現代牙科集團有限公司 (簡稱「現代牙科」或「本集團」，股份代號：03600.HK) 欣然公佈截至2025年12月31日止年度(「年度」) 業績。截至2025年12月31日止年度，在牙科行業數碼化趨勢持續的支持下，本集團的多維度策略及持續提升的營運效率及生產力，使其於本期間的收益、純利及EBITDA數字均創下紀錄新高。雖然期內宏觀經濟環境充滿挑戰，牙科手術的需求普遍疲弱，且貿易戰存在不確定性，然而仍然創下紀錄。本集團利用位於泰國、越南及中國內地的國際生產設施，積極應對前所未有的國際貿易環境。全球數碼化趨勢持續推動義齒行業的整合，使本集團進一步擴大其市場份額。我們持續的數碼轉型措施提升客戶及病人體驗的同時，進一步使本集團在競爭對手中脫穎而出，表現優於同業。本集團的相關基礎仍然穩固，並將全力以赴把握未來機遇。歐洲市場業務截至2025年12月31日止年度，歐洲市場錄得收益約18.9億港元，較去年增加約2.7億港元，此地理市場佔本集團收益總額50.5%。歐洲市場收益增加主要由於新產品的推出(例如數碼化義齒)及我們最先進的數碼化流程，推動銷售訂單量增加。本集團已成為提供全面數碼化解決方案的先驅，範圍涵蓋多項微創及美容義齒解決方案以至口腔內部掃描儀及透明矯正器，本集團已準備好把握牙科行業數碼化趨勢加速帶來的機遇。本集團繼續透過所建立，重點為教育及數碼化且非常鄰近客戶的牙科生態系統解決方案，積極從國際及本地競爭對手取得市場份額；透過不同的境內及境外資源有效地滿足我們客戶的高期望。本集團一直致力並將繼續裝備好自己，為市場上的牙科領域提供最先進的數碼化解決方案。北美市場業務於截至2025年12月31日止年度，北美市場錄得收益約7.0億港元，較去年減少約5,570萬港元，此地理市場佔本集團收益總額約18.6%。我們在北美地區的大部分業務包括MicroDental Laboratories, Inc.及其附屬公司(「MicroDental集團」)在本地製造的高端產品。雖然2025年對主動美容治療的需求仍然疲弱，然而我們的中央化數碼流程及對區內廣泛生產單位的網絡讓我們為北美客戶交出更高服務質素及營運效率。我們位於美國、中國、越南及泰國等地的多元化供應基地，繼續在應對美國關稅的不確定性時帶來更大彈性－此為將我們與競爭對手作區分的優勢。雖然進口產品線的數碼化帶動大型市場個案的增長，然而2025年4月在美國實施的關稅帶來新的不確定性及為我們以進口為主的業務單位的銷售帶來緩慢增長。大中華市場業務截至2025年12月31日止年度，大中華市場錄得收益約6.2億港元，較去年減少約4,685萬港元，此地理市場佔本集團收益總額約16.5%。中國內地市場面對帶量採購政策及價格激烈競爭延長的逆境，而於2025年下半年情況開始穩定。此亦導致中國內地牙科診所積極於香港推廣種植牙治療(香港患者就診人數明顯減少)。本集團有意退出低利潤分部，並專注於中及高價值客戶，確保本集團業務能夠長期及可持續獲利。本集團對此市場的中長期前景感到樂觀，特別是在政府最新的採購相關措施中，預計(i)規範義齒價格及建立價格透明度，平衡中心點；(ii)讓本集團領先的品牌名稱及聲望成為客戶及顧客的主要考量；及(iii)讓本集團從其龐大生產團隊中得益及根據顧客或客戶有效分配資源的能力。澳洲市場業務截至2025年12月31日止年度，澳洲市場錄得收益約2.9億港元，較去年增加約2,438萬港元，此地理市場佔本集團收益總額約7.7%。澳洲的收益錄得增長，反映牙科行業數碼化趨勢帶動大量新的數碼化產品，以及收購Digital Sleep的收益貢獻，但部分被相較於截至2024年12月31日止年度，澳元兌港元貶值2.4%所抵銷。透過我們不同的品牌(可提供境內及境外製造的產品)，憑藉涵蓋從經濟及標準至優質/精品等的多種價位，本集團能夠有效地滲透整個澳洲市場。我們投資於本地產能，以為客戶提供更快捷的服務，並可供選擇產品之生產地。本集團為澳洲市場最大參與者之一並為市場內主要企業牙科團體的首選供應商。其他市場其他市場主要包括泰國、印度洋國家、馬來西亞、台灣及新加坡。截至2025年12月31日止年度，該等市場錄得收益約2.5億港元，較截至2024年12月31日止年度增加約1.8億港元。此地理市場佔本集團收益總額約6.7%。其他市場的收益增加主要由於新收購的Hexa Ceram帶來的收益貢獻所致。未來前景及策略全球宏觀經濟環境仍然不明朗，地緣政治的緊張局勢及關稅的潛在變動繼續營造不利環境。然而，本集團的生產遍及全球各地，而全球分銷網絡讓我們在面對該等挑戰時享有獨特優勢。有別於依賴單一國家生產的一眾競爭對手，我們的營運遍佈中國、越南及泰國(包括新收購的Hexa Ceram)等地，讓我們面對挑戰時能夠進退有據，靈活應變。此策略連同我們快速適應當地市場環境的能力，使本集團降低風險，同時把握各地區的新興機遇。牙科行業繼續展現卓越的適應力，在不可逆轉的人口趨勢下加以突顯，包括人口老化及人們對口腔健康的意識提高，持續帶動義齒的長期需求。本集團建基於2025年創記錄的表現而處於有利位置，能夠保持良好勢頭，同時進一步強化市場的領導地位。行業數碼化勢不可擋，加快義齒行業的整合。我們處於轉型的尖端，目前數碼化解決方案個案佔總銷量約35至40%。我們的中央化數碼工作流程、有關口腔內部掃描儀的夥伴關係、專有的解決方案及全球教育中心有助提升營運效率、縮短處理時間及提供卓越的客戶體驗。有關措施創造高進入門檻，並將於未來數年繼續擴大利潤及增加市場份額。在成功整合於2025年1月收購的泰國最大牙科實驗室Hexa Ceram及Digital Sleep Design(用於治療阻塞性睡眠窒息症的專利尼龍口腔矯正器)後，我們在東南亞地區的影響力及專業能力已經大幅提升。是次擴張連同我們位於美國、中國、越南及泰國等地的多元化供應基地，讓我們在應對潛在的貿易及其他地緣政治風險時帶來更大彈性，同時支持區內快速交付。展望將來，本集團仍然致力透過多角度方針強化其全球領導地位。我們將繼續尋求具針對性的收購、合營企業及夥伴關係，以擴大及補充我們所提供的產品，特別是我們高增長的透明矯正器TrioClear，同時加強我們的分銷及銷售網絡。我們在大型生產設施、AI、自動化、研發及數碼創新方面的持續投資，使效率大幅增高，從而確保我們一直處於行業尖端。關於現代牙科集團現代牙科集團有限公司 (股份代號: 03600.HK) 為全球領先的義齒器材供應商、經銷商和顧問，專注於發展迅速的義齒行業為客戶提供定制式義齒。我們的產品組合大致可分為三類﹕固定義齒器材，例如牙冠及牙橋；活動義齒器材，例如活動義齒；及其他器材，例如正畸類器材、透明牙套、運動防護器及防鼾器。 現代牙科集團擁有多個備受稱許的全球品牌，包括西歐的Labocast、Permadental及Elysee Dental、中國的洋紫荊牙科器材、香港的現代牙科器材、美國的Modern Dental USA及MicroDental、澳洲及新西蘭的Modern Dental Pacific、新加坡的Modern Dental SG、臺灣的 Modern Dental TW、馬來西亞的 Apex Digital Dental及泰國的Hexa Ceram等。我們提供穩定和優質的產品及卓越的客戶服務，令這些公司品牌能茁壯成長。我們於全球超過 28個國家擁有超過 80 家服務中心及服務逾 35,000 名客戶。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HIGHLIGHTS:- Total gross billings amounted to approximately RMB3,955.0 million, representing an increase of approximately 12.8% from approximately RMB3,505.9 million for the corresponding period.- Total revenue was approximately RMB3,430.1 million, representing an increase of approximately 48.7% from approximately RMB2,306.0 million for the corresponding period.- The profit attributable to Shareholders of the Group was approximately RMB921.8 million, representing an increase of approximately 238.5% from approximately RMB272.4 million for the corresponding period.- Non-HKFRS adjusted profit for the year (excluding the share-based compensation expenses) was approximately RMB1,022.5 million, representing an increase of approximately 191.8% from approximately RMB350.5 million for the corresponding period.- Taking into account the financial and cash flow positions of the Group, the Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash), and the proposed final dividend is subject to consideration and approval by Shareholders at the AGM.HONG KONG, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - JF SmartInvest Holdings Ltd (the “Company” ; together with its subsidiaries, the "Group" or “we”) is pleased to announce its consolidated annual results for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, leveraging its “technology + investment research” dual-drive strategy, the Group achieved outstanding performance. Supported by robust cash flow and profitability, the Board has proposed a final dividend of HK$0.36 per share, bringing the total dividend for the full year to approximately HK$407.4 million when combined with the interim dividend already paid, reflecting its commitment to delivering returns to shareholders.Strong Financial Performance with Substantial Profitability ImprovementDuring the Reporting Period, the Group continued to advance product innovation, AI applications, and investment research capabilities, driving solid growth across its business. Total revenue for the year reached RMB3,430.1 million, representing a YOY increase of 48.7%. Gross profit amounted to RMB2,821.0 million, up 48.9% YOY, while the gross profit margin remained at a high level of 82.2%, indicating the favourable economies of scale and earnings quality of the Group’s business model.In terms of profitability, profit attributable to equity shareholders surged by 238.5% YOY to RMB921.8 million. Excluding share-based compensation expenses, non-HKFRS adjusted profit for the year reached RMB1,022.5 million, representing a YOY increase of 191.8%, fully demonstrating the effective strategy execution and market adaptability of the Group.The Group places great emphasis on shareholder returns. The Board recommends the payment of a final dividend of approximately HKD168.5 million for the year ended December 31, 2025, representing HKD0.36 per share (in cash). Together with the interim dividend of approximately HK$238.9 million already distributed, the total dividend for 2025 will amount to approximately HK$407.4 million. The steady dividend policy fully reflects the Group’s ample cash reserves and its firm confidence in future development prospects.Continued Optimisation of Product Matrix and Enhancement of Diversified Service SystemDuring the Reporting Period, the Group continued to build a diversified product matrix, enriching its product portfolio in response to different customer needs. VIP products 'Stock Navigator, Super Investor' were steadily optimized, with the addition of several quantitative products and AI-powered products. We also launched a 24/7 AI intelligent customer service system, which significantly improved service efficiency. The live streaming system was upgraded, with sessions increasing by 36% YOY and average daily unique viewers exceeding 100,000.Relying on an integrated “AI + content + service + tools” solution, the Enjoy-Stock Pad recorded net sales volume exceeding 75,000 units during the Reporting Period. The Jiuyao Stocks launched over 80 lightweight products, converting professional investment research capabilities into standardised products. The SmartInvest APP completed its strategic transformation from a tool to a platform, with monthly active users increasing by more than 40% YOY and the 30-day retention rate remaining above 50%.The Group further enhanced its product matrix with two new products, Decision Master and Star-tier Services, filling the gap in the mid-tier product system and enabling a seamless trading service experience. Decision Master focuses on three AI+ investment research modules - themes, value investing and quantification - comprehensively enhances investment decision-making capabilities of individual investors. Star-tier Services collaborates with multiple securities brokerages and partners to create a fully integrated closed-loop ecosystem of“tools-services-trading”, serving over 50,000 users during the Reporting Period.Guided by Technological Innovation, Striving Towards “Investment Advisory Intelligent Agent 2.0”The Group regards innovation and technological R&D as its core driving force, accelerating its transformation towards “digital intelligence”, and advancing towards the era of “investment advisory intelligent agent 2.0”. During the Reporting Period, R&D expenses amounted to approximately RMB356 million, with R&D personnel reaching 624, a YOY increase of approximately 42.8%. The Group held 158 software copyrights and patents in AI, big data and product features, with 22 new items added on a year-on-year basis.The self-developed FinSphere Agent Large Model Assistant V3.0 passed the Large Model Assistant Functionality Completeness Test conducted by the China Academy of Information and Communications Technology, becoming the first large-model application in the securities industry. During the Reporting Period, it served approximately 664,000 customers with cumulative services of 22.58 million. The digital intelligent investment robo-advisor “Jiu Ge” served approximately 600,000 customers with cumulative services exceeding 19 million. The Group also launched stock diagnosis intelligent agent 4.0, AI Xiaoce Q&A assistant, and established an intelligent compliance and risk control platform covering the entire business workflow, indicating that the group's AI capabilities have gradually been implemented in core scenarios.To strengthen its technological foundation, the Group established a technology subsidiary, Jiufang Zhiqing, and set its foothold in “Shanghai Foundation Model Innovation Center”, China’s first large model innovation ecosystem community. The subsidiary serves as the Group’s core AI vehicle for operating a native service technology system, promoting the deep application of AI in scenarios such as investment research, investor education, and risk control.Deep-Rooted Investment Research as the Cornerstone, Adhering to Buyer-Side Advisory and Deepening the “1+N” Investment Research SystemThe Group continues to deepen its “1 research institute and N business lines” investment research system, with the JF Financial Research Institute as investment research hub. The Institute has established a pyramidal-structured professional talent echelon led by Chief Economist Dr. Xiao Lisheng, comprising 4 experts, 8 super-IPs and 128 professionals. As of the end of the Reporting Period, the Group had 576 employees holding securities investment advisory qualifications and 2,628 employees holding securities practitioners, maintains a leading team scale and structure in the industry.During the Reporting Period, The Institute conducted more than 300 research activities, covering more than 2,000 listed companies. The Institute authored approximately 1,200 in-depth research reports and 45 sets of thematic courses with a total duration of 2,000 minutes, continuously enhancing the professional capabilities of buyer-side consultants.Multi-Dimensional, Full-Funnel Traffic Operation to Unlock New Growth DimensionsDriven by AI technology, the Group positions refined MCN-based traffic operations as a central hub connecting users with its business, building an integrated, synergistic omni-channel traffic ecosystem comprising “public-domain MCN (multi-platform) + private-domain + proprietary APP”. On the technological front, the Group applied AIGC to restructure content production, shifting from manual creation to “human-machine collaboration” model, and established a data flywheel integrating “advertising data, model training and operational automation”. During the Reporting Period, the Group consolidated its leading position on online short-video and live streaming platforms’ operations, established a multi-platform coordinated traffic matrix, and developed a multi-tiered, high-quality content ecosystem. It also pioneered e-commerce models for the Enjoy-Stock Pad and AppStore models for the APP, driving deep integration between traffic operations and product features.Future OutlookMr. Chen Wenbin, chairman of the Board and chief executive officer of JF SmartInvest Holdings Ltd, said: “In 2025, we remained committed to the dual-drive strategy of ‘technology + investment research’. Not only did we achieve leapfrog growth in performance, but we also successfully led the industry into the era of ‘Investment Advisor Agent 2.0’. Leveraging artificial intelligence and big data technologies, we developed AI products such as the JF Robo-Advisor, FinSphere Agent and FinSphere Report, achieving industry-leading innovations and scenario-based applications, helping users accomplish the critical transition from ‘cognitive improvement’ to ‘decision optimisation’. At the same time, we transformed our professional investment research capabilities into easily accessible lightweight services, realising a strategic shift ‘from tool to platform’. We uphold the principles of rational investing, value investing and long-term investing, assisting clients in developing sound investment philosophies.“In the future, the Group will focus on four key strategic dimensions. First, deepening AI-driven empowerment across all scenarios, accelerating the iteration of AI agents and their commercialisation on the consumer side, and driving the Group’s digital and intelligent transformation. Second, leveraging Forthright Securities and Forthright Capital’s licenses, advancing the globalisation strategy by exporting the Jiufang’s core models, accelerating overseas business expansion. Meanwhile, promoting license upgrading and strategic investment layout to further improve the construction of digital asset infrastructure. Third, strengthening product-driven business diversification and synergies, deepening cooperation with licensed financial institutions such as securities brokerages, and building a service closed loop covering pre-investment, in-investment and post-investment. Fourth, continuing to optimize the customer operation system, unlocking the value of traffic through full-funnel traffic initiatives, and achieving long-term customer retention. We are dedicated to making investing simpler and more professional while enhancing investors’ sense of fulfillment in investment and wealth management.”About JF SmartInvest Holdings Ltd (Stock Code: 9636)JF SmartInvest Holdings Ltd is a new generation stock investment assistant. The Company is engaged in the provision of equity investment instruments, securities investment advisory, investor education and other services to individual investors. The products include stock quote software, the AI Stock Machine, Stock Navigator, Super Investor and Jiuyao Stocks. The Company adopts the technology + investment research model, develops JF Robo-Advisor, FinSphere Agent, FinSphere Report and other products based on artificial intelligence (AI) and big data technology, which are applied to the industry in terms of innovative practice and scenario application.For enquiries, please contact:Financial PR (HK) LimitedEmail: ir@financialpr.hkTel: 852 2610 0846Fax: 852 2610 0842 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

摘要：- 總訂單金額約為人民幣3,955.0百萬元，較同期的約人民幣3,505.9百萬元增加約12.8%。- 總收益約為人民幣3,430.1百萬元，較同期的約人民幣2,306.0百萬元增加約48.7%。- 股東應佔溢利約為人民幣921.8百萬元，較同期的約人民幣272.4百萬元增加約238.5%。- 非香港財務報告準則下經調整年內溢利（剔除以股份為基礎的薪酬開支）約人民幣1,022.5百萬元，較同期的約人民幣350.5百萬元增加約191.8%。- 董事會建議派發末期股息約168.5百萬港元，即每股0.36港元（現金），建議末期股息須待股東於股東週年大會上審議及批准。香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 九方智投控股有限公司（「九方智投控股」或「公司」；及其附屬公司統稱「本集團」或「我們」）欣然宣佈截至2025年12月31日止年度（「2025年」或「報告期內」）之綜合年度業績。報告期內，本集團踐行「科技＋投研」雙輪驅動戰略，錄得良好業績表現。基於強勁的現金流與盈利表現，董事會建議派發末期股息每股0.36港元，連同已派發的中期股息，全年累計派息總額約407.4百萬港元，積極回報股東支持。財務表現強勁 盈利能力大幅提升報告期內，本集團持續推進產品創新、AI應用及投研能力建設，帶動整體業務穩健增長。年度總收益達人民幣3,430.1百萬元，同比增長48.7%；毛利達人民幣2,821.0百萬元，同比增長48.9%，毛利率維持在82.2%的高水平，反映本集團業務模式具備良好的規模效益及盈利質量。盈利表現方面，股東應佔溢利同比大幅上升238.5%至人民幣921.8百萬元。若剔除以股份為基礎的薪酬開支，按非香港財務報告準則計算的經調整年內溢利達人民幣1,022.5百萬元，同比增長191.8%，顯示公司戰略執行持續見效，並具備良好的市場應變能力。本集團始終重視股東回報，建議派發2025年度末期股息每股0.36港元，派息總額約168.5百萬港元。連同已派發的中期股息約238.9百萬港元，本集團2025年全年派息總額約為407.4百萬港元。穩健的派息政策充分反映集團充裕的現金儲備，以及對未來發展前景的堅定信心。持續優化產品矩陣 推動多元化服務體系建設報告期內，本集團持續構建多元化產品矩陣，圍繞不同客群需求不斷豐富產品組合。VIP產品（股道領航、超級投資家）穩步迭代，新增多款量化及AI產品，並上線7×24小時AI智能客服，進一步提升服務效率；直播體系亦全面升級，場次同比增加36%，日均總UV超過10萬。依託「硬件＋AI＋內容＋服務」一體化方案，「易知股道」AI股票機於報告期內淨銷量超7.5萬台，用戶使用時長及黏性均保持良好水平；「九爻股」累計推出80餘款輕量化產品，將專業投研能力轉化為標準化產品，有效降低個人投資者參與門檻；「九方智投APP」則實現由工具向平台的戰略轉型，報告期內月活用戶同比增長超40%，30日留存率維持在50%以上，整體用戶黏性持續提升。此外，本集團進一步完善產品矩陣，推出「決策大師」及「星級服務」兩大新產品，填補中端產品空缺，跑通交易鏈路。其中，「決策大師」聚焦AI＋題材、價投及量化三大投研模組，協助個人投資者提升自主決策能力；「星級服務」則聯動券商及合作夥伴，打造「工具—服務—交易」一體化生態閉環，報告期內服務用戶規模超過5萬。以科技創新為核心　全力邁向「投顧智能體2.0」本集團視創新和技術研發為核心驅動力，全速推進全面「數智化」戰略，深耕證券領域「人工智能+」應用，全力邁向「投顧智能體2.0」時代。報告期內，研發投入約人民幣356百萬元，研發人員達624人，較同期增長約42.8%；在人工智能、大數據及產品功能等領域共擁有軟件著作權及專利158件，同比新增22件。自研的「九方靈犀」大模型助手V3.0通過中國信息通信研究院大模型助手功能完備性測試，成為證券行業首個獲此認證的大模型應用。報告期內，該產品服務客戶約66.4萬人，累計服務達2,258萬次；智能投顧數字人「九哥」服務客戶約60萬人，累計服務超1,900萬次。公司亦推出診股智能體4.0智能體工具、AI小策問答助手，構建了覆蓋業務全流程的智能合規風控平台，逐步將AI能力深度賦能各大業務核心場景並形成規模化應用。為進一步強化技術基礎，本集團設立科技子公司九方智擎並入駐全國首個大模型創新生態特區「模速空間」，作為集團AI技術核心載體，搭載原生服務技術體系，推動AI在投研、投教、風控等場景深度落地。以深度投研為基石 堅持買方投顧 深化「1+N」投研體系本集團持續深化「1個研究所，N條業務線」投研體系，以九方金融研究所為投研中樞，推動專業能力滲透至業務全流程。研究所目前已建立以首席經濟學家肖立晟博士為核心，聯動4名專家、8名超級IP及128名專業人員組成的金字塔式團隊。截至報告期末，本集團擁有576名具備證券投資顧問資格及2,628名具備證券業資格的員工，專業團隊規模及結構均保持行業領先。報告期內，研究所完成上市公司、行業論壇及券商策略會等調研超300場，研究覆蓋約2,000家上市公司，並深度跟蹤其中1,500家；全年累計撰寫約1,200篇深度報告，並開發45套專題課程，總時長達2,000分鐘，持續鞏固買方投顧專業能力。多維全域流量運營 拓展業務增長新維度本集團以AI技術為核心驅動力，將MCN精細化流量運營定位為連接用戶與業務的核心樞紐，構建「公域MCN＋私域＋自有APP」三位一體、協同聯動的全域流量體系。技術層面，公司深度應用AIGC重構內容生產，從人工創作轉向「人機協同」，並搭建起「投放數據－模型訓練－運營自動化」的數據飛輪。報告期內，本集團持續鞏固線上短視頻直播平台的領先運營優勢，搭建多平台協同流量矩陣，打造多層次優質內容生態。同時創新探索AI股票機電商模式與APP應用市場，推動流量運營與產品特性深度適配。展望未來九方智投控股董事會主席及首席執行官陳文彬先生表示：「2025年，我們始終堅持『科技＋投研』雙輪驅動策略。我們不僅實現了業績的跨越式增長，更成功引領行業邁向『投顧智能2.0』時代。基於人工智能與大數據技術，我們研發了九方智能投顧數字人、九方靈犀、九方智研等AI產品，實現了行業領先的創新實踐與場景應用，助力用戶完成從『認知提升』到『決策優化』的關鍵轉化。同時，我們將專業的投研能力轉化為觸手可及的輕量化服務，實現了由『工具向平台』的戰略轉型。我們貫徹理性投資、價值投資和長期投資理念，幫助客戶構建正確的投資觀。未來，本集團將聚焦四大戰略維度：第一，深化AI全場景賦能，加速投顧智能體迭代與C端商業化落地，驅動公司全面數智化轉型；第二，充分利用方德證券、方德資本牌照資源優勢，深化全球化戰略佈局，輸出九方核心模式，加速海外業務拓展，並推進數字資產相關牌照升級與戰略投資，完善數字資產基礎設施搭建；第三，強化產品力驅動多元協同，深化與券商等持牌金融機構的合作，構建涵蓋投前、投中、投後的服務閉環；第四，持續優化客戶經營體系，透過全域化流量佈局深挖流量價值，實現客戶長效留存。我們致力于让投資理財變得更簡單、更專業、提升投资理财的幸福感。」關於九方智投控股有限公司九方智投控股有限公司作為新一代股票投資助手，面向廣大個人投資者提供股票投資工具、證券投資顧問、投資者教育等服務，相繼推出股票行情軟件、AI股票機、股道領航、超級投資家、九爻股等產品。該公司通過「科技＋投研」模式，基於人工智能（AI）與大數據技術研發九方智能投顧數字人、九方靈犀、九方智研等AI產品，實現行業創新實踐與場景應用。如有垂詢，請聯絡：金融公關（香港）有限公司電郵：ir@financialpr.hk電話：852 2610 0846傳真：852 2610 0842   Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SINGAPORE, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) - Choosing where to place your savings in Singapore is an important financial decision that requires careful consideration. With many banks offering different types of accounts, it is easy to get confused. However, picking the right one is the first step to reaching your financial goals, whether you are saving for a dream wedding, a new home, or a retirement fund.The good news is that you no longer need to spend a whole afternoon waiting at a bank branch. You can now open a bank account online in just a few minutes using your phone or computer. Here is a simple guide to help you choose the best account for your needs in 2026.Identify Your Financial HabitsBefore focusing on interest rates, consider how you manage your money on a daily basis. Savings accounts in Singapore usually fall into two categories:The Active Saver: These accounts give you high interest rates, but you have to make a few mandatory transactions each month. Usually, you need to credit your salary and spend a set amount on your credit card.The Passive Saver: These accounts help you earn bonus interest just for keeping your money in the account and letting it grow. You do not need to worry about credit card spending or paying bills.Compare Interest RatesBefore opening a bank account online, make sure you compare the interest rates. Many basic accounts offer low interest rates. To make your money grow, you should look for bonus interest.For example, a high-interest account can offer between 2% and 5% depending on the rules you follow. If you have SGD 50,000, the difference between a basic account and a high-interest one could be hundreds of dollars in extra cash every year. Always check the effective interest rate, which tells you the real amount you will earn after all the levels are counted.Look for Welcome PromotionsBanks in Singapore are always competing for your business. When you open a bank account online, you can often grab a welcome gift, such as cash credits or rewards. These promotions are a great way to get a head start on your savings. Just make sure to check the dates, as many of these flash deals only last for a few months.Check the Fees and MinimumsEven a great account can lose you money if you are not careful about fees. Before you sign up, check for these three things:Minimum balance: Most accounts require maintaining a certain amount of money in the account at all times. If the balance drops below this limit, the bank may charge you a monthly fee.Initial deposit: Some accounts require at least SGD 1,000 to get started.ATM access: Make sure the bank has plenty of ATMs near your home or office so you do not get charged for using the machine of another bank.Open an Account OnlineOnce you have picked the right account, the final step is to fill out your application. In Singapore, you can use Singpass MyInfo to fill out your application automatically.When you open a bank account online, your details, such as your NRIC, address, and income, are pulled directly from the government database, thus reducing paperwork. Most accounts are approved almost instantly, and you can start using your new digital card right away.Final ThoughtsChoosing a savings account is not just about finding the highest interest rate. It is about finding the one that fits how you live. If you are a busy professional who already uses a credit card, an active account is perfect. If you just want to set your money aside and forget it, a passive account is better.By taking 10 minutes to compare your options today, you can ensure that every dollar you earn works as hard as you do.Disclaimer: This article is for general information only and does not have any regard to the specific investment objectives, financial situation and particular needs of any specific person. The views expressed in this article are solely those of the author. This article shall not be regarded as an offer, recommendation, solicitation or advice. You may wish to consult your own professional advisers about this article, in particular, a financial professional before making financial decisions. Any past events, trends and/or performance referred to in this article may not necessarily be indicative of future events, trends or performance. This article is based on certain assumptions and reflects prevailing conditions as at the time of publication, which are subject to change at any time without notice. The author and publisher of this article as well as any other parties associated with this article make no representation or warranty of any kind, whether express, implied or statutory, in respect of this article and accept no liability or responsibility for the completeness or accuracy of this article or any error, inaccuracy or omission relating to this article and/or any consequence, injury, loss or damage howsoever suffered by any person relating to this article, in particular, arising from any reliance by any person on this article. Publishers or platforms may be compensated for access to third party websites.Contact Information:Name: Sonakshi MurzeEmail: Sonakshi.murze@iquanti.comJob Title: ManagerSOURCE: iQuanti Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 近日，2026中關村論壇年會在北京隆重舉行。作為國家級科技創新交流合作平臺的重要參與者，百望股份受邀出席本次國家級科技創新交流盛會，並在"東盟創新合作發展論壇"中發表了重磅主題演講。論壇上，百望股份聚焦跨境貿易合規痛點，推介全球智能稅務合規平臺Tax Swift。它內置百望自研的AI稅務引擎、百望指數與國家適配器，依托覆蓋全球的稅務規則知識庫，動態監控、AI分析、自動更新，打造起全球貿易的"合規路由器"，為國際經貿合作注入合規新動能。論壇聚焦科技創新，跨境合規成全球貿易核心命題2026年中關村論壇年會，是經國務院批准、以"科技創新與產業創新深度融合"為年度主題，由科技部、國家發展改革委、工業和信息化部、國家國資委、中國科學院、中國工程院、中國科協和北京市政府共同主辦。大會匯聚了100多個國家和地區的全球頂尖科學家、企業家及國際組織代表，上千名嘉賓共同搭建起中國與世界科技創新交流的橋梁。作為本次中關村論壇的重要平行論壇，東盟創新合作發展論壇聚焦中國與東盟科技創新協同、產業融合發展、跨境貿易便利化等核心議題，匯聚東盟各國政、產、學、研各界代表，交流研判破解區域經貿合作中的共性難題。在主題演講環節，百望股份圍繞著"AI賦能中企出海：構建全球化合規新底座"展開了深度分享。當前，全球貿易一體化進程不斷加快，跨國經營的業務蓬勃發展，但稅務合規難題始終是制約全球貿易高效推進的關鍵瓶頸。尤其是東盟這樣的活力經濟體，區域內各國經貿往來頻繁，跨境交易規模持續攀升，市場主體對於交易效率、交易合規有著更高的需求和更迫切的期待，而區域內各國稅務政策、技術標准的差異，卻成為了制約中國-東盟跨境貿易提質增效的重要因素。從實踐來看，國際貿易稅務合規難題呈現多元化、複雜化態勢：- 語言與格式壁壘凸顯，不同標准、規範讓企業票據解讀成本高、理解易出偏差；- 各國財稅政策碎片化嚴重，差異性的稅種、稅率、申報流程，讓企業難以精准掌握；- 技術標准不統一，系統接口、數據傳輸缺乏規範，各類操作繁瑣且效率低下；- 跨境交易鏈條長、涉及主體多，企業難以實現全流程風險檢測；這些難題不僅增加了企業跨境經營的成本，更成為制約企業融入全球產業鏈、拓展國際市場的關鍵瓶頸。百望股份的Tax Swift平臺，正是破解合規困境、保駕跨境貿易的全新技術創新，尤其為中國-東盟跨境貿易合規發展提供了高效可行的思路。Tax Swift重磅亮相，全鏈路一站式賦能國際貿易合規作為百望股份的深耕全球稅務合規領域、布局國際化市場的核心成果，Tax Swift一次適配，就可幫助企業構建起覆蓋"票據處理-納稅申報-風險管控"的全鏈路跨境稅務合規服務體系：一是全球AI全鏈路票據處理能力，可打破語言與格式壁壘。國際化引擎、發票引擎、稅務引擎與國家適配器，四重引擎自動協同運轉，完成智能算稅、智能識別等，一套架構適配全球業務場景。企業無需手動幹預任何細節，即可完成多語言、多幣種、多時區的票據管理工作，完美適配東盟各國票據規範與業務場景。二是全球AI一鍵申報，打通跨境稅務申報便捷通道。Tax Swift現已與20多國國稅局直連，全球稅務規則知識庫動態更新、AI分析引擎自動掃描規則變化，聯動發票識別引擎與全球交易計稅規則引擎實時響應，將全球申報工作壓縮成一個動作：一鍵登錄，自動填飽，實時同步狀態，可大幅提升東盟跨境貿易稅務申報效率。三是全球AI稅務顧問，提供全周期政策支撐。平臺內置超3萬條國際財稅規則，覆蓋200+國家稅種與費金，通過實時聯動發票引擎與稅務引擎，實現AI自動解讀、自動更新，及時識別和處置異常變化，幫助企業精准把握區域政策動態、規避合規風險，尤其針對東盟各國稅務政策的更新與調整實現實時響應。三大AI能力模塊的協同運作，為企業建立起全球合規洞察的能力，構築起清晰可控的合規管理邊界。當前，全球貿易格局深度調整，合規已成為企業跨境經營的核心競爭力，百望股份"貿易無國界、納稅有主權"的理念，精准契合了出海企業的合規需求。依托全球化戰略布局，百望股份持續推進TaxSwift產品迭代落地，自2025年8月啟動以來，產品已完成1.0版本全球電子發票布局，並在2026年加速海外數據中心與算力中心部署，加速東南亞、歐盟、中東等區域市場的拓展，向著建設覆蓋80+CTC國家的全球AI票稅合規平臺快速演進。而東盟作為百望股份全球化出海的先鋒陣地，憑借區域內旺盛的跨境貿易合規需求，成為 Tax Swift 落地應用的核心市場，已有眾多企業與百望股份達成深度合作，其中越南、新加坡、印度尼西亞等東盟國家的企業、高校更是與百望攜手，共同探索跨境稅務合規的數智化解決方案，讓 Tax Swift的技術能力與服務體系更好地適配東盟市場需求。依托中關村論壇及東盟創新合作發展論壇的開放平臺，更多國際嘉賓尤其是東盟各國代表，對百望股份的數智解決方案有了進一步了解。深耕財稅數智領域十餘年，百望股份已經累計處理發票數量逾260億張，對應交易總額高達1188.0萬億元，服務的納稅人識別號數量更是突破了9640萬家，這些豐富的實踐經驗與數據智能領域的深厚沉澱，贏得了與會嘉賓產生了高度關注與廣泛認可。未來，百望股份將持續深化Tax Swift平臺的迭代升級，重點打磨適配東盟市場的產品能力與服務體系，打造一流的全球稅務合規智能體平臺，進一步拓展全球服務範圍，幫助更多跨境經營的國際企業開拓發展、贏得未來！ Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- Annual sales of HuaTangNing exceeded 4 million packs, a year-on-year increase of 91%, with revenues reaching RMB 492.9 million, a year-on-year increase of 93%, marking outstanding results from the Company’s fully independent commercialization operation.- Delivered record financial performance, with profit before tax reaching RMB 1,106.4 million; maintained a robust bank balance and cash position of RMB 1,092.3 million at year-end, laying a solid foundation for sustainable operations and growth.- Gross margins rose to 56.9%, and selling expenses as a percentage of revenue were optimized to 33.6% from 59.9%, significantly enhancing profitability.- HuaTangNing  renewed its listing in the new National Reimbursement Drug List (NRDL) at the same price in 2025 for the calendar years 2026 and 2027, reaffirming its clinical and innovative value.- With the approval of PTE, market exclusivity in China granted another 5 years to April 2034, further strengthening commercial certainty.- Dorzagliatin was approved for commercialization in Hong Kong as HYHOMSIS®, accelerating its global expansion toward South-East Asia.- Multiple real-world evidence published to demonstrate therapeutic advantage of dorzagliatin.- Continuous expansion of therapeutic potential of glucose homeostasis and initiation of new first-in-disease indications study covering diabetes prevention, rare diseases, mild cognition impairment and frailty.SHANGHAI, Mar 27, 2026 - (ACN Newswire via SeaPRwire.com) – Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025 (the “Reporting Period”). During the Reporting Period, the commercialization of HuaTangNing (dorzagliatin tablets), the Company’s core product – the global first-in-class innovative anti-diabetes medicine, glucokinase activator (GKA) – advanced comprehensively across all fronts, the Company’s independent commercialization team was efficiently and seamlessly established in its first year of operations, the Company’s R&D pipeline continued to be enriched, and the Company’s financial performance achieved a historic breakthrough, successfully entering a new stage of profitability, injecting strong momentum into the innovative development of the global diabetes treatment field.Dr. Li CHEN, Founder and CEO of Hua Medicine, stated: “2025 is a remarkable year in the commercialization operation of Hua Medicine. The Company has successfully advanced from R&D to commercialization driven organization and achieved the fully independent capacity in commercialization of global first in class novel glucose homeostasis regulator HuaTangNing. With strong market execution and product competitiveness, we have achieved nearly triple-digit growth in sales volume and revenue over 2024 when the commercialization was farmed out to sales and marketing partners. At the same time, the Company has made key progress in global market expansion through registration of drozagliatin in Hong Kong and position it toward 700 M population in south-east Asia. We continue to expand the clinical application of glucose homeostasis regulation technology and engage in new indications such as early-stage Alzheimer’s disease and Frailty. The first-in-disease efforts in GCK-MODY and Frailty set the new innovation course of Hua Medicine in the next 5 years.” Business Highlights and Operational Progress- Fully Powered Commercialization, Historic Breakthrough in ProfitabilityOn January 1, 2025, the Company assumed full responsibility for the commercialization of HuaTangNing, allowing the company to consolidate both operational and strategic control over market execution in China. The Company successfully built a professional sales team covering 10 sales regions around the country, focusing on marketing, medical affairs and commercial operation. Through an AI-empowered digital commercialization platform, operational efficiency and sales productivity were greatly enhanced, injecting new vitality into the Company’s commercial development.Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. Since its launch in October 2022, HuaTangNing has been prescribed to over 500,000 patients through 3,000+ hospitals, community centers, pharmacies and online channels.Sales performance exceeded expectations, with 4.011 million packs of HuaTangNing sold during the reporting period, representing a 91% increase over the fiscal year 2024. This growth was achieved at the same price for both periods, underscoring strong demand and successful execution of Hua’s commercial strategy.In terms of profitability, the Company’s gross profit reached approximately RMB280.4 million, a year-on-year increase of 125%. Thanks to expanded production scale and optimized manufacturing processes, the Company’s gross margin improved to 56.9%,  increasing by 8.2 percentage points as compared to 48.7% for the year of 2024. Selling expenses increased only by RMB12.3 million to RMB165.5 million, reflecting a significant positive trend towards profitability when our selling expenses in the 2025 fiscal year represents only 33.6% of revenue, whereas in the 2024 fiscal year, our selling expenses represented approximately 59.9% of revenue. In fiscal year 2025, our commercialization efforts achieved profits of approximately RMB114.9 million (as defined by gross profits less selling expenses). Although we expect to continue to increase personnel to our commercialization team, we expect this profitability trend in our commercial operations in mainland China to continue.Following the termination of the collaboration with Bayer at the end of 2024, dorzagliatin achieved a record-high sales volume. Profit before tax increased to RMB1,106.4 million for the fiscal year 2025. We ended fiscal year 2025 with a cash position of approximately RMB1,092.3 million.- Accelerated Global Layout, Strengthened Core Rights and InterestsThe Company took a key step in global expansion. On February 27, 2026, dorzagliatin (trade name: MYHOMSIS®, was successfully approved for marketing by the Hong Kong regulatory authority. The Company plans to officially launch the product in the Hong Kong market by the middle of 2026 and further expand to Asian regions. In addition, the Company submitted a new drug registration application in Macau in 2025.The Company also made new progress in intellectual property protection. In February 2026, the patent term extension (PTE) application for dorzagliatin was formally approved by the China National Intellectual Property Administration, thereby the core patent protection period of dorzagliatin extended to April 2034 and an additional 5-year market exclusivity obtained, which provides a strong guarantee for the product’s long-term market competition.In 2025, dorzagliatin was recognized as national innovation and an effective therapy for chronic diseases by the regulatory authorities in China. Accordingly, the same NRDL price was offered for the calendar years 2026 and 2027. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption. The Company will continue to safeguard the product’s market competitiveness and patient accessibility and accelerate the popularization of the drug among patients.- Advancement of Real-World Studies, Continuous Validation of Clinical ValueReal-world evidence (RWE) studies continue to corroborate the key role of dorzagliatin in improving glucose-dependent pancreatic islet secretion function, and demonstrate its efficacy in diabetes prevention, remission, and delaying or preventing diabetes complications.The RWE study sponsored by Hua Medicine HMM0701 with 380 T2D patients was fully enrolled in 2025. The interim analysis, as reported at the 2025 American Diabetes Association (ADA), showed that 86% of such patients were taking two or more antidiabetic drugs and 41% of such patients were using insulin. After a 6-month treatment, a significant improvement of glycemic control was observed with HbA1c reduction from 8.1% to 7.3% with the mean time-in-range (TIR) levels increasing to over 70%. Thus far, the studies have demonstrated that when dorzagliatin is administered in combination with other antidiabetic drugs, such patients have experienced significantly improved post-meal glucose levels and improved β-cell function.Separately, a mechanistic study with dorzagliatin (employing double-tracer measurement) was conducted in the United States to provide scientific evidence of hepatic glycogen formation in T2D patients with an average of 17 years of diagnosed diabetes. In this study, patients were treated with dorzagliatin twice daily for 6 weeks. The results showed that dorzagliatin increased direct glucose flux to hepatic glycogen implying the improvement of restoration of hepatic Glucokinase (GK) function. Together with the clinical research data that dorzagliatin improves early phase insulin release and GLP-1 secretion, recovery of hepatic glycogen synthesis in T2D patients offers an important path in controlling post-meal glucose excursion and provides a unique opportunity in controlling diabetes complications, such as diabetes kidney diseases and mild cognition impairment.The RWE sponsored by Hua Medicine (HMM0601) has completed clinical trials with over 2,000 subjects, with average diabetes duration of 7.9 years and above 30% having disease duration more than 10 years. The initial results suggest that dorzagliatin is safe and well tolerated in Chinese T2DM patients. There were no new adverse effects observed in the study and the incident rate remains as low as what was observed in Phase III clinical trials. Patient adherence was generally high, with a mean adherence rate of approximately 95%. In this study, 80% of the participants have used one or more oral anti-diabetes medicine, and 20% used insulin. Dorzagliatin demonstrated good efficacy and safety not only in the overall population but also in elderly, obese, and hyperglycemic patient populations, whether used as monotherapy or in combination with metformin, SGLT2 inhibitors, insulin, and other medications. The topline results will be reported at the 2026 American Diabetes Association.- Deepened Clinical R&D, Continuous Expansion of New IndicationsNew Indication for Dorzagliatin – MODY-2 Patients.Medical experts in mainland China and Hong Kong have conducted independent clinical and preclinical studies of dorzagliatin for MODY-2 treatment. MODY-2, also called GCK-MODY, is a monogenic disease in which patients have a genetic defect of glucokinase gene (GCK) which results in elevated blood glucose and significant reduction of the second phase insulin secretion. The population of GCK-MODY patients is approximately 1.7 million in China. These patients are diagnosed with diabetes at a young age and represent an unmet medical need given that currently available medications are not effective. In clinical studies with MODY-2 patients, China investigators have reported that dorzagliatin is effective in reducing blood glucose levels to normal levels in MODY-2 patients who previously failed to manage their elevated blood glucose levels when treated with metformin, TZD, DPP-IV inhibitors, and SGLT-2 inhibitors. Additional results demonstrated that a single dose of dorzagliatin improved overall glucose sensitivity and second phase insulin secretion significantly in GCK-MODY patients, suggesting a unique mechanism of action of dorzagliatin to regulate GLP-1 secretion. Based on such results, Hua Medicine has communicated and reached a consensus with the CDE at NMPA to file the IND submission of dorzagliatin for MODY-2 patients in 2026.Dorzagliatin for Diabetes Prevention.Prevention of diabetes is an important focus at Hua Medicine. There are approximately 1.12 billion people living with prediabetes worldwide. We have initiated SENSITIZE 3 clinical study in Hong Kong in pre-diabetic (IGT) subjects and in early diabetes patients. These studies represent first-in-disease studies. In this double-blinded placebo-controlled study, we will evaluate the blood glucose management and pancreatic function under IVGTT and OGTT conditions to better define the clinical treatment baseline and endpoints. We expect to complete this study in 2026 and explore the opportunity to file IND applications of dorzagliatin for diabetes prevention in China and Asian Pacific regions thereafter. Dorzagliatin for Neurodegenerative Diseases.MCI shows approximately 15.5% prevalence among elderly people in China and approximately 22% in the US, and is common in T2D patients with a 45% incidence rate. The development of dorzagliatin for neurodegenerative disease is a new focus in our drug discovery efforts. Through the Genome-Wide Association Study (GWAS) and Mendelian Randomization (MR) study, we have realized the important role of GCK gene activation in the prevention of memory loss and cognitive impairment in humans. It has also come to our attention that post-meal glucose excursion is closely related to Alzheimer disease and dementia. The bio-energy balance in the brain is largely dependent on the glucose homeostasis control in the peripheral organ and the neural network communication in the central and peripheral system via spatial temporal management. Impaired glucose homeostasis and diabetes conditions result in a reduction of glucose transporter expression and insulin receptor expression in the brain, which can be prevented by low dose dorzagliatin. We have realized the potential of dorzagliatin in the treatment of mild cognitive impairment (MCI) and will initiate these first-in-disease clinical studies in the future.Dorzagliatin for Frailty.Frailty is an age-related geriatric syndrome characterized by reduced tolerance to internal and external stressors. Approximately 17% of Americans and 11% of Asians over the age of 50 suffer from frailty, while pre-frailty affects roughly 50% and 47% of these populations, respectively. It is not a single-organ disease, but the consequence of dysregulated multisystem homeostasis. Genetic evidence supports the causal effects of glucokinase (GK) activation on lowering frailty risk. We plan to initiate clinical studies in the future to advance dorzagliatin’s application in frailty.Development of combination therapy for diabetes and complications.Dorzagliatin rescues pancreatic function in glucose insulin secretion and GLP-1 secretion, as evidenced by clinical and basic research results. It also improves hepatic insulin sensitivity and reduces hepatic insulin resistance through recovery of hepatic glycogen synthesis in T2D patients. The combination of dorzagliatin with DPP-IV inhibitors, SGLT-2 inhibitors, and GLP-1 agonists have demonstrated effective regulation of lipid metabolism. Studies in combination with anticancer PI3K inhibitors have also offered unique benefits for glucose homeostasis management.- Diversified Product Pipeline, Innovative Layout for Future GrowthHua Medicine continues to enrich its pipeline layout based on core products. The Company has accelerated the R&D of a fixed-dose combination (FDC) of dorzagliatin and metformin as a twice-daily therapy for Type 2 diabetes patients with inadequate glycemic control on metformin alone, to further improve patient medication compliance. The product is supported by the strong results of the loose-dose combination in both Phase III clinical trials and real-world use. The Company has submitted an IND application to NMPA, and the GMP commercial manufacturing process has been successfully carried out, preparing for the pivotal bioequivalence study for NDA filing in 2027. Clinical studies have shown that the combination of dorzagliatin and metformin can better control blood glucose, reduce postprandial blood glucose and improve fasting blood glucose, providing new clinical value for optimizing blood glucose homeostasis endpoints.We have advanced our 2nd generation GKA as a once daily therapy for patients with obesity, leveraging dorzagliatin effects in improved glucose-stimulated GLP-1 secretion in the pancreas and in the intestine. The MAD study of the 2nd generation GKA was initiated in the United States with first-patient-in in December 2025, and we expect to report topline data by the middle of 2026.Meanwhile, the Company is also exploring combination therapy regimens of dorzagliatin with GLP-1 receptor agonists, SGLT-2 inhibitors and other drugs. In a recently published clinical trial in China, researchers reported the superior benefits of our dorzagliatin in combination with semaglutide as compared to semaglutide alone in a 12-week study. The combination group showed superior results across several key measures, including glycemic control, bodyweight related indicators and β-cell function.Financial Summary- Revenue generated by the Company was approximately RMB 492.9 million from the sale of approximately 4.011 million packs of HuaTangNing, increases of approximately 93% and 91% respectively, as compared with the year ended December 31, 2024.- Gross profit generated by the Company for the year ended December 31, 2025, was approximately RMB280.4 million, representing an increase of approximately 125%, as compared with the year ended December 31, 2024, and gross margins rose to 56.9%.- Profit before tax increased by approximately 542% to approximately RMB1,106.4 million for the year ended December 31, 2025, as compared with the year ended December 31, 2024.- Bank balances and cash position was approximately RMB1,092.3 million as of December 31, 2025.- Expenditures incurred by the Company for the year ended December 31, 2025, were approximately RMB433.4 million.Forward-Looking StatementsThis document contains statements regarding Hua Medicine's and its products' future expectations, plans and prospects. Such forward-looking statements relate only to events or information as of the date on which the statements are made in this document and are subject to change in light of future developments. Except as required by law, the Company shall not be obligated to update or publicly revise any forward-looking statements or unforeseen events after the date of such statements, whether as a result of new information, future events or other circumstances. Please read this document carefully and understand that actual future performance or results of the Company may differ materially from expectations due to various risks, uncertainties or other statutory requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment. In February 2026, dorzagliatin (Trade name: MYHOMSIS®,) was approved for marketing by the Pharmaceutical Services of the Department of Health of the Government of the Hong Kong Special Administrative Region of China.For more informationHua MedicineWebsite: www.huamedicine.comInvestorsEmail: ir@huamedicine.comMediaEmail: pr@huamedicine.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

- 华堂宁(R)全年銷量超400萬盒，同比增長91%，銷售額達4.929億元，同比增長93%，公司全面自主商業化運營成效卓著。- 實現創紀錄盈利，稅前盈利達11.064億元；現金餘額穩健，截至年末達 10.923億元，為持續運營發展奠定堅實基礎。- 毛利率提升至56.9%，銷售開支占比從59.9%優化至33.6%，盈利能力顯著增強。- 华堂宁(R)原價續約新版醫保目錄，2026-2027年維持2025年的價格不變，臨床價值和創新價值再獲認可。- 隨著PTE獲批，中國市場獨佔權獲5年延期至2034年4月，商業確定性進一步提升。- 多格列艾汀（HYHOMSIS(R) ，華領片(R)）獲得香港地區上市批准，加速其面向東南亞的全球擴張進程。- 發佈多項真實世界證據，證實多格列艾汀治療優勢。- 持續拓展血糖穩態治療潛力，啟動多項全新的疾病首創新適應症研究，研究範圍涵蓋糖尿病預防、罕見病、輕度認知障礙及衰弱症領域。上海, 2026年3月27日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥（「公司」，香港聯交所股份代號：2552）宣佈公司及其附屬公司截至2025年12月31日止年度（「報告期」）經審核的綜合業績。報告期內，公司核心產品、全球首創抗糖尿病新藥、葡萄糖激酶激活劑（GKA）华堂宁(R)（多格列艾汀片）實現全方位推進，公司自主商業化團隊於運營首年即實現高效組建和運轉，研發管線持續豐富，財務表現實現歷史性突破，成功邁入盈利新階段，為全球糖尿病治療領域的創新發展注入強勁動力。華領醫藥創始人、CEO陳力博士表示：「2025年是華領醫藥商業化運營中的意義非凡的一年。公司成功完成從研發驅動型組織向商業化驅動型組織的轉型，具備了全球首創新藥、血糖穩態調節劑华堂宁(R)的完全自主商業化運營能力。憑藉強勁的市場執行力與產品競爭力，相較於2024年將商業化業務委託給營銷合作夥伴的階段，公司的銷量與營收實現了近三位數的增長。與此同時，通過推動多格列艾汀在香港的註冊工作，公司在全球市場拓展方面取得了關鍵性進展，我們將向覆蓋7億人口的東南亞地區進行市場佈局。我們持續拓展血糖穩態調控技術的臨床應用場景，積極佈局早期阿爾茨海默病、衰弱症等新適應症領域。針對GCK-MODY及衰弱症開展的疾病首創新藥研發工作，將為華領醫藥未來五年的創新發展劃定全新方向。」業務亮點與運營進展- 商業化全面發力，盈利實現歷史性突破2025年1月1日起，公司正式全面接管华堂宁(R)在中國的商業化工作，獲得全部運營與戰略主導權，公司成功搭建了專業的銷售團隊，覆蓋全國10個銷售區域，專注於產品營銷、醫學事務及商業運營。通過人工智能賦能的數字商業化平台，運營效率與銷售生產力大幅提升，為公司商業化發展注入新活力。受益於國家醫保藥品目錄的持續廣泛覆蓋，华堂宁(R)在二級和三級醫院的處方量顯著增長，患者可及性不斷提高，通過3000多家醫院、社區衛生中心、藥房和線上渠道，惠及超過50萬名患者。報告期內，產品銷量達401.1萬盒，同比增長91%；銷售額達4.929 億元，同比增長93%，在單價保持穩定的情況下，充分印證了市場需求的強勁增長和自主商業化團隊的高效執行能力。盈利能力方面，2025年，公司毛利達到2.804億元，同比增長125%，得益於生產規模擴大及製造工藝優化，公司毛利率從2024年的48.7% 提升至56.9%，增加8.2個百分點；銷售開支僅增長1230萬元至1.655億元，占收入比例優化至33.6%，較2024年的59.9%大幅下降；商業化業務實現約1.149億元盈利（按毛利扣除銷售開支計算）。公司預期仍將持續擴充商業化團隊規模，但商業化運營的盈利趨勢也將持續增長。在2024年底終止與拜耳合作後，多格列艾汀銷售額創歷史新高，報告期內，公司稅前盈利增加至人民幣11.064億。截至2025年末，現金結餘約為人民幣10.923億元，穩健的現金情況為公司持續發展奠定了堅實基礎。- 全球佈局加速推進，核心權益得到強化公司全球化佈局邁出關鍵步伐。2026年2月27日，多格列艾汀（香港地區商品名：MYHOMSIS(R)，華領片(R)）成功獲得香港監管機構的上市批准，公司計劃2026年中正式在香港市場推出該產品，並將進一步向亞洲地區拓展。此外，公司已于2025年向澳門藥監局遞交華領片(R)（MYHOMSIS(R)）的新藥上市申請。公司在知識產權保護方面也再獲進展。2026年2月，中國國家知識產權局批准多格列艾汀專利期限補償（PTE）申請，核心專利保護期延長至2034年4月，新增5年市場獨佔權，為產品長期市場競爭提供有力保障。2025年，多格列艾汀獲中國監管機構認定為國家級創新藥及慢病有效治療藥物，國家醫保局已確認，2026-2027年，华堂宁(R)的國家醫保目錄價格維持不變，公司將持續保障產品的市場競爭力和患者可及性，尤其在二級和三級醫院，加速患者的用藥普及。- 真實世界研究推進，臨床價值獲持續驗證真實世界證據（RWE）研究持續佐證多格列艾汀在葡萄糖依賴性胰島分泌功能改善中的關鍵作用，並顯示其在糖尿病預防、緩解及延緩或預防糖尿病併發症方面的功效。HMM0701已完成入組，共招募380名2型糖尿病患者。2025年6月，在美國ADA年會上發表的中期分析結果顯示，86%的患者同時服用兩種或以上降血糖藥物，41%的患者使用胰島素。經6個月治療後，血糖控制明顯改善，糖化血紅蛋白由8.1%降至7.3%，平均TIR（目標範圍內時間）提升至70%以上。迄今為止的研究顯示，多格列艾汀與其他降糖藥物聯合使用時，患者的餐後血糖水平和β細胞功能均顯著改善。另外，在美國進行的多格列艾汀機制研究（採用雙示蹤劑測量法），為平均確診糖尿病17年的2型糖尿病患者的肝糖原生成提供了科學證據。在該研究中，患者每日服用兩次多格列艾汀，持續6周。結果顯示，多格列艾汀能增加葡萄糖直接流入肝糖原的通量，意味著其有助於恢復肝臟GK功能。結合臨床研究數據顯示，多格列艾汀可改善早期胰島素釋放和GLP-1分泌，恢復2型糖尿病患者的肝臟GK功能，不僅為控制餐後血糖波動提供重要途徑，並在控制糖尿病併發症（如糖尿病腎病變及輕度認知障礙）方面提供獨特契機。HMM0601研究已經完成臨床試驗，共納入2000名受試者，平均患病時間為7.9年，其中超過30%患病時間超過10年。初步結果顯示，多格列艾汀在中國2型糖尿病患者中安全性、耐受性良好。研究中未觀察到新的不良反應，不良反應發生率維持在III期臨床試驗中觀察到的低水平，患者的用藥依從性普遍較高，平均依從率約為95%。在本研究中，80%的受試者已使用一種或多種口服降血糖藥，20%的受試者使用胰島素。多格列艾汀不僅在整體患者群體中展現出良好的療效及安全性，在老年、肥胖及高血糖患者群體中同樣有效，無論作為單藥治療或與二甲雙胍、SGLT-2抑制劑、胰島素及其他藥物聯合使用。頂線結果將於2026年ADA年會上發表。- 臨床研發持續深化，新適應症不斷拓展多格列艾汀用於治療MODY-2患者。中國內地及香港地區醫學專家已獨立開展多格列艾汀用於MODY-2治療的臨床研究及臨床前研究。MODY-2（又稱GCK-MODY）是一種單基因疾病，患者因葡萄糖激酶基因(GCK)存在遺傳缺陷，導致血糖升高及第二時相胰島素釋放顯著減少。在中國，MODY-2患者群體規模約為170萬人。此類患者確診糖尿病時年齡偏小，且由於現有治療藥物療效不佳，這一患者群體存在未被滿足的醫療需求。中國研究人員在針對MODY-2患者的臨床研究中報告指出，對於先前使用二甲雙胍、TZD、DPP-4抑制劑及SGLT-2抑制劑仍無法控制高血糖的MODY-2患者，多格列艾汀能有效將血糖降至正常水平。其他結果顯示，單劑量多格列艾汀可顯著改善這類患者的整體葡萄糖敏感性及第二時相胰島素分泌，表明多格列艾汀具有調節GLP-1分泌的獨特作用機制。基於以上結果，華領醫藥已與國家藥品監督管理局（NMPA）藥品審評中心溝通，將於2026年提交多格列艾汀用於MODY-2患者的IND申請。多格列艾汀用於糖尿病預防。糖尿病預防是華領醫藥的重要研發重點。公司已於香港啟動針對糖尿病前期糖耐量異常（IGT）受試者及早期糖尿病患者的SENSITIZE 3臨床研究。這項雙盲安慰劑對照研究將評估受試者在靜脈葡萄糖耐量試驗及口服葡萄糖耐量試驗下的血糖控制及胰島功能，以更明確界定臨床治療基線及終點指標。我們預計於2026年完成研究後，將在中國及亞太地區探索提交多格列艾汀用於糖尿病預防的IND申請的新機遇。多格列艾汀用於神經退行性疾病。研究顯示，中國老年人的輕度認知障礙患病率約為15.5%，美國則約為22%；該症狀在2型糖尿病患者中也相當常見，發病率達45%。多格列艾汀用於神經退行性疾病的研究已成為公司藥物研發工作的新焦點。通過全基因組關聯分析(GWAS)及孟德爾隨機化（MR）研究，我們發現GK基因激活在預防人類記憶力衰退及認知障礙方面具有重要作用。同時我們也發現，餐後血糖波動與阿茲海默症及失智症密切相關。血糖穩態異常及糖尿病狀況會導致大腦葡萄糖轉運蛋白及胰島素受體表達減少，而低劑量多格列艾汀可預防該功能損傷。我們已確認多格列艾汀在治療輕度認知障礙方面的潛在價值，並將於未來啟動針對該疾病領域的首創療法的相關臨床研究。多格列艾汀用於治療衰弱症。衰弱症是一種與年齡相關的老年綜合症，其特徵為對內外應激因子的耐受性降低。約17%的美國人及11%的亞洲人（50歲以上）患有衰弱症，而處於衰弱症前期者則分別約占此兩個群組的50%及47%。衰弱症並非單一器官疾病，而是多系統內穩態失調所導致的後果。遺傳學證據支持GK激活對降低衰弱症風險具有因果作用。我們計劃於未來啟動臨床研究，以推進多格列艾汀在衰弱症治療領域的應用。聯合用藥用於糖尿病及併發症的治療。臨床與基礎研究結果顯示，多格列艾汀能恢復胰腺在葡萄糖刺激下的胰島素及GLP-1分泌，也可以通過恢復2型糖尿病患者肝臟葡萄糖激酶功能，改善肝臟胰島素敏感性並降低肝臟胰島素抵抗。多格列艾汀與DPP-4抑制劑、SGLT-2抑制劑及GLP-1受體激動劑的聯合使用已證明可有效調節脂質代謝，與抗癌PI3K抑制劑聯合使用的研究也為血糖穩態管理帶來獨特優勢。- 產品管線豐富多元，創新佈局未來增長華領醫藥在核心產品基礎上持續豐富管線佈局。依託多格列艾汀與二甲雙胍聯合用藥在III期臨床試驗和真實世界應用中取得的優異數據，公司加速推進多格列艾汀與二甲雙胍固定複方製劑（FDC）的研發。該製劑為每日兩次給藥方案，適用于單用二甲雙胍血糖控制不佳的2型糖尿病患者，旨在以進一步提升患者的用藥依從性。公司已向NMPA提交IND申請文件。此外，GMP商業化生產工藝也已成功開展，為2027年新藥上市申請的關鍵生物等效性研究做好準備。臨床研究顯示，多格列艾汀與二甲雙胍聯用能夠更好地控制血糖，降低餐後血糖，改善空腹血糖，為優化血糖穩態終點提供了新的臨床價值。第二代GKA的研發取得重要突破。作為肥胖2型糖尿病患者每日一次治療的緩釋新片劑，公司已在美國啟動多格列艾汀多劑量遞增（MAD）研究，以探討第二代GKA在血糖穩態控制方面的療效及新藥的作用機制，首例患者已於2025年12月入組，預計2026年中公佈頂線數據。同時，公司還在探索多格列艾汀與GLP-1受體激動劑、SGLT-2抑制劑等藥物的聯合治療方案。近期，在一項中國的臨床試驗中，研究者報告：多格列艾汀聯合司美格魯肽治療12周，療效顯著優於司美格魯肽單藥治療。聯合治療組在血糖控制、體重相關指標及β細胞功能等多項關鍵指標上均表現更優。財務摘要截至2025年12月31日，- 华堂宁(R)全年銷量約401.1萬盒，相較2024年全年，同比增長91%，實現營收約4.929億元，同比增長93%。- 毛利約人民幣2.804億元，同比增長125%，毛利率提升至56.9%；- 稅前盈利約人民幣11.064億元，較2024年增長542%；- 銀行結餘及現金約人民幣10.923億元，資金狀況穩健；- 總開支約人民幣4.334億。前瞻性聲明本文包含有關華領醫藥以及產品未來預期、計劃和前景的陳述。該等前瞻性陳述僅與本文作出該陳述當日的事件或資料有關，可能因未來發展而出現變動。除法律規定外，於作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請仔細閱讀本文並理解，由於各種風險、不確定性或其他法定要求我們的實際未來業績或表現可能與預期有重大差異。關於華領華領醫藥（「本公司」）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥彙聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品华堂宁(R)（多格列艾汀片）以葡萄糖傳感器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，华堂宁(R)已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。2026年2月，多格列艾汀（商品名：MYHOMSIS(R)，華領片(R)）獲得中國香港特別行政區政府衛生署藥物辦公室的上市批准。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com新聞免責聲明本材料，如為上下文論述的準確性和完整性，提及在中國上市的產品相關信息的，特別是標識或要求，應遵循中國監管機構批准的相關文件。另外，相關信息不應被解讀為對任何藥物或者診療方案的推薦或者宣傳，亦不應替代任何醫療衛生專業人士的醫療建議，涉及醫療的相關事宜務必諮詢醫療衛生專業人士。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com